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Abstract 
The burden of Cardiovascular Diseases (CVDs) is remarkable in Palestine, which is 
considered the first leading cause of death and placing a huge pressure on healthcare 
economics. Several imaging approaches exist for diagnosing Coronary Artery Disease 
(CAD), with varying accuracy and cost. In the Gaza Strip, there is a trend in the Ministry 
of Health (MoH) toward the need for a sufficient evidence base to justify the cost of any 
procedure. We aimed to provide cost-effectiveness information to help physicians and 
decision-makers in selecting the most appropriate testing strategy.  
This prospective study was conducted to assess the cost-effectiveness of coronary 
computed tomography angiography (CCTA) compared with invasive coronary 
angiography (ICA) in patients with suspected CAD. The overall sensitivity and specificity 
of CCTA technique was 97.3% and 90.48%, respectively. The positive predictive value 
was 94.74% and the negative predictive value was 95% of CCTA. 
The overall direct costs of ICA (234.23 dollars) were found to be about 4.6 times the cost 
of CCTA (50.84 dollars). Cost of unnecessary and adverse health outcome of ICA is 
prominent in this study, about 43.6% of patients have not any benefit from ICA procedure 
with unjustified cost 26621 dollars for the investigated patients' cohort.  
The cost of CCTA per patient increased as a linear function of increasing CAD prevalence. 
In contrast, the cost per patient for ICA did not increase significantly. Specifically, CCTA 
showed lower cost than ICA with CAD prevalence <57% but higher costs with CAD 
prevalence ≥57%. 
Regarding cost-effectiveness per CAD correct diagnosis, it is worthy to mention that at 
CAD prevalence 55% both of CCTA and ICA were equally effective with a cost of 448 
dollars. But, the data showed that CCTA is more cost-effective in patients with a 
prevalence up to 54%, ranging from 1139.1 dollars (10% prevalence) to 449.7 dollars 
(54% prevalence). In contrast, ICA showed better cost-effectiveness for the prevalence 
above 55%, ranging from 436.13 dollars (56% prevalence) to 244.23 dollars (100% 
prevalence). 
In term of quality-adjusted life years gained (ΔQALY) with cost-effectiveness, the trend 
was similar in which at a CAD prevalence of 55% CCTA and ICA were equally effective 
(150 dollars). But, CCTA was more cost-effective up to a CAD prevalence of 54% ranging 
from 399.21 dollars (10% prevalence) to 128.06 dollars (54% prevalence). In contrast, ICA 
shows better cost-effectiveness for the prevalence above 55%, ranging from 146.55 dollars 
(56% prevalence) and 81.79 dollars (100% prevalence). 
The study highly recommends ICA to be considered for patients with CAD whose clinical 
characteristics indicate a high prevalence of severe stenosis and when the benefits are 
deemed to exceed the risk. Patients with suspected CAD should receive a comprehensive 
medical history to assess the probability of CAD prior to additional testing. Furthermore, 
CCTA can be useful as a first-line test for risk assessment in patients with mild to 
intermediate probability of suspected CAD. 
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Chapter1: Introduction 
1.1 Background  
The initial diagnosis and treatment of patients with suspected coronary artery disease 
(CAD) can reduce adverse health events and persist in life (Gibbons et al., 2003). 
Currently, invasive coronary angiography (ICA) is regarded as the ‗gold standard‘ for the 
assessment of coronary anatomy and the presence, localization, and severity of CAD. 
However, ICA has obvious limitations. It has a substantial procedural cost and it is an 
invasive method associated with serious risks with severe long-term consequences the 
composite rate of death, stroke or myocardial infarction is 0.1-0.2% in elective procedures 
(Tavakol et al., 2011).  Most importantly, ICA does not directly assess the condition of 
atherosclerotic disease and change within the vessel wall but merely allows assumptions on 
its presence and extent based on lumen obstruction. Images are obtained in only two 
dimensions through the use of multiple projections enables a more comprehensive 
assessment of an individual lesion. Besides, according to the previous study, more than 50 
% of the subjects who undergo elective ICA have no significant coronary artery stenosis 
(Patel et al., 2010). Therefore, a comparably accurate, non-invasive and reliable screening 
modality for detecting CAD is of major interest.   
Multislice computed tomography (MSCT) as diagnostic equipment has been developing 
rapidly in recent years. Dramatic improvements in MSCT create high-quality diagnostic 
images (three dimensions, morphology and functional) (Budoff et al., 2006a). In addition, 
obvious benefits (i.e., low cost, shorter acquisition time and non-invasive nature) were 
recorded with the procedure conducted by MSCT, which known as coronary computed 
tomography angiography (CCTA) (Mowatt et al., 2008a). The role of CCTA was proved in 
enabling the rapid identification and assessment of atherosclerosis within the moving 
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coronary arteries and creating considerable interest in the perception that MSCT might 
potentially reduce the need for ICA (Stein et al., 2006). 
The accuracy and reliability of CCTA were validated in 2008 with the publication of three 
landmark controlled clinical trials (Budoff et al., 2008; Meijboom et al., 2008; Miller et al., 
2008). Since the publication of these landmark trials, we have seen frequent technological 
progression in the field of coronary imaging.  
It is generally believed that in the near future, the use of CCTA may replace a substantial 
proportion of ICA examinations, especially for assessing the degree of stenosis and 
patency of grafts (Mowatt et al., 2008b). Anyway, it is necessary to address these 
perspectives by creating a model to project clinical outcomes, and cost-effectiveness of 
CCTA, as compared with ICA, in the evaluation of patients with suspected CAD. 
Cost-effectiveness analysis (CEA) provides a framework of different management 
strategies for maximizing health benefit within the constraint of inadequate resources 
(Weinstein and Stason, 1977). Cost-effectiveness analysis is an analytical approach that 
integrates a test‘s clinical effectiveness with its economic value (Mark, 2002). The study of 
CEA provides a rational means to balance health care quality and clinical value in terms of 
the best outcome at a reasonable price. The economic evaluation suggests that strategies 
including CCTA are likely to be considered cost-effective for image patients with CAD 
and cost saving while yielding approximately the same amount of quality-adjusted life-
years (QALYs) compared to ICA (Westwood et al., 2013). 
Continuous development and upgrading in the radiology departments have remarked over 
the last seven years in the Gaza Strip (GS) hospitals. This progress open the gate to make 
comparative studies in the diagnosis of the CAD with health impact and cost containment 
by different modalities. 
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1.2 Research problem 
Cardiovascular disease (CVD) is a major public health issue over the world. An estimated 
17.9 million people died from CVD in 2016, representing 31% of global deaths. Of these 
deaths, an estimated 7.4 million were due to CAD (WHO, 2017). The burden of CVD is 
high in Palestine, which is the first leading cause of death in 2016 (30.6% of annual 
reported deaths) (MoH, 2017).  
Coronary Artery Disease is rapidly placing an huge strain on healthcare economics. The 
diagnosis of CAD is performing through a series of clinical and imaging exams. For 
patients with evident symptoms of CAD, an initial invasive approach with ICA is usually 
recommended. Many researchers agree that it is not logical to perform noninvasive 
imaging prior to ICA on high-risk emergency patients because these procedures could 
delay treatment. As an alternative to invasive and expensive ICA, non-invasive imaging 
techniques are used to detect asymptomatic CAD patients at an initial stage and guide 
optimal patient management thereafter (Meijboom et al., 2006; Scheffel et al., 2007; 
Bettencourt, 2009; Catalán et al., 2011). 
Nowadays, the need for healthcare cost-containment becomes one of the main aims of all 
health providers. In the Gaza Strip (GS), which is under strict siege and shortage of 
resources, there is a trend in the Ministry of Health (MoH)  toward the need for a sufficient 
evidence base to justify the cost of any procedure or therapy. Despite the continuing 
interest in health economic research, little accessible data was recorded on cost-
effectiveness analysis. This gap is also noticeable in the diagnosis of different cases with 
CAD. This vital shortage creates difficulties for decision makers who must allocate scarce 
resources within the radiology and cardiovascular fields. 
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1.3 Justification and significance of the study 
Patients with CVD risk have a substantial economic burden on the budget of the Gaza strip 
hospitals. However, observable improvement in the diagnosis and treatment of CAD was 
achieved in the Gaza strip hospitals. The ICA is considered one of the best choices for 
diagnosis CAD and remains the cornerstone of diagnosis and treatment of patients with 
significant or unstable chest pain symptoms. In another hand, ambiguous policy in the 
patient flow process for the successful diagnostic performance measure. Thus, it can 
prevent the use of the invasive diagnostic procedure in some patients (non-significant 
CAD). There is a gap in information about the advantage of MSCT, as a new non-invasive 
diagnostic technology in the diagnosis of the CAD. Through our literature reviewing there 
is no previous study touching this subject in Gaza hospitals. In this study, a comparison in 
cost-effectiveness between CCTA versus ICA was projected at governmental hospitals in 
the Gaza Strip. Moreover, the diagnostic performance of CCTA was closely measured to 
test the appropriateness of this comparison with a focus on the diagnostic accuracy and 
prognostic value in CAD. 
1.4 Aim of the study 
The overall aim of this study is to assess the cost-effectiveness of coronary computed 
tomography angiography (CCTA) compared with invasive coronary angiography (ICA) in 
order to diagnosis patients with suspected coronary artery disease (CAD).  
1.5 Specific objectives 
1. To assess key principles between CCTA and ICA as cost-effectiveness analysis. 
2. To evaluate the accuracy of CCTA as an alternative diagnostic procedure for ICA to 
improve health outcomes for patients with suspected CAD. 
 
 
5 
 
1.6 Research questions 
1. What is the relative cost-effectiveness of the CCTA imaging compared to that of ICA 
for the diagnosis of patients with suspected CAD? 
2. Is CCTA accurate and effective non-invasive imaging tool to evaluate patients with 
CAD? 
3. What is the efficacy of patient selection for diagnostic ICA in suspected CAD? 
4. Is it time for CCTA to replace ICA in diagnostic CAD? 
5. Does the use of CCTA result improve downstream health outcome? 
1.7 Context of the study 
This study was conducted in MSCT and Catheterization departments at Al-Shifa hospital. 
Therefore, it is helpful to understand the conditions that contribute to the impact on the 
Palestinian health care and special departments that we have mentioned and their impact 
on the Palestinian population in general and the beneficiaries of the service in particular 
system. So, the researcher represents some basic information on the demographic context, 
the Palestinian people, and the Palestinian economy, which may interact with each other to 
influence the health status and health care services in Palestine. 
1.7.1 Demographic context of Palestine  
Palestine is situated on the eastern coast of the Mediterranean Sea, with an entire area of 
27.009
 
square kilometers (sq.km), it stretches from Ras Al- Nakoura in the north to Rafah 
in the south. Palestine has an important strategic geographic location as it is situated on the 
western edge of the continent of Asia, the eastern coastal extremely of the Mediterranean 
Sea, it is boarded by Lebanon in the north, the Gulf of Aqaba in the south, Syria and 
Jordan in the east by Egypt and Mediterranean Sea in the west (Annex1). Palestinian 
National Authority (PNA) controls two geographically separated areas, West Bank (WB) 
and Gaza Strip (GS). The Palestinian Central Bureau of Statistics (PCBS) estimates that in 
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2017 the total population of Palestine is 4,781,248 people, about 2,433,196 males 
compared to 2,348,052 females. The estimated population of West Bank is 2,881,957, 
60.3% of which 1,470,293 males compared to 1,411,664 females. On the other hand, the 
population of Gaza Strip for the same year is about 1,899,291, 39.7% of the total 
population of Palestine, including 962,903 males compared to 936,388 females (PCBS, 
2018). Gaza Strip is a small piece of land located in the southern area of Palestine, It is 
divided into five governorates: North Gaza, Gaza City, Mid Zone, Khan Younis and Rafah 
(Annex 2).  
1.7.2 Socioeconomic context  
The economic situation in the GS is characterized by tragic and limited income, the 
unemployment rate remarkably increased to 43.9% (PCBS, 2018), the problematical 
political and economic situation deteriorate the life of people. People suffer from the tight 
siege that restricts passing of goods and aids across the borders. 
The deterioration of both economic and social status in the GS harmfully affects the status 
of the population and the economic recovery became impossible as long as the siege 
remains. In the Gaza Strip, the closure and intra-Palestinian political divide create specific 
challenges, including restrictions on staff movement, access difficulties for patients 
demanding professional services outside the Gaza Strip. As a result, people have been 
forced to receive medical services in government hospitals because of their inability to pay 
for treatment in private centers. Consequently, it has become a great burden rest with the 
Ministry of Health in the Gaza Strip. 
1.7.3 Palestinian health care system 
Health care system plays a critically important role in improving health. Well-functioning 
health system enables the achievement of good health with the efficient use of available 
resources (McKee et al., 2009). In the Gaza Strip, health care services are provided mainly 
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through four sectors, governmental health services at Ministry of Health (MoH), Non-
Governmental Organizations (NGOs), United Nations Relief and Works Agency 
(UNRWA), and the Private Sector. 
MoH provides primary, secondary, and tertiary health services and purchases the 
unavailable tertiary health services from domestic and abroad providers. UNRWA 
provides primary care services for refugees and purchases secondary care services for 
special cases. NGOs provide primary, secondary and some tertiary services. The private 
for-profit sector provides the three level of care through a variety of specialized hospitals 
and investigation centers. The disintegration in the health care system and the lack of 
coordination between various sectors increase the challenges to provide optimal health care 
services. 
1.7.4 Al-Shifa Medical Complex Center 
Al-Shifa complex medical center is the largest hospital in Gaza. It‘s situated in the west 
part of Gaza City. It was established in 1946, developed over years until it reaches to 
higher universal level over 45,000 thousand square meters and located on the western side 
of the middle of Gaza City. It contains three hospitals Surgery, Internal Medicine and 
Maternity. The health services delivered to populations through the three hospitals and 
include the different patients referred by emergency departments or clinics by primary 
care. Where it is transported to internal departments or hospital outpatients review the 
complex. Total number of beds are 590 and while the total number of employees is about 
1600 divided as follows: Nursing 36.5%, doctors 35.6%, administrators and x-ray 
technicians in different disciplines17.7%. Bed occupancy rate during the past six months is 
about 82% (MoH, 2016). 
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1.7.5 Radiology departments at Al-Shifa hospital  
The radiology department at Al Shifa is the largest departments at the level of the Gaza 
Strip, which receives a large number of patients from Gaza City and other governorate 
hospitals. Radiology departments of the hospital consist of conventional basic radiography, 
fluoroscopy, mammography, dental panorama, magnetic resonance imaging (MRI) and 
multislice computed tomography (MSCT). 
1.7.6 Evolution of MSCT in Gaza Strip 
The first MSCT department was developed at Public Aid Hospital as a non-governmental 
organization in January 2012. Coincide with that, another device was developed at the 
European Gaza Hospital. In January 2015, a new department has been developed at Al-
Shifa hospital, bringing the total number of MSCT in the Gaza Strip to three departments. 
These MSCT machines have advanced options to perform cardiac imaging. Recently, 
others MSCT machines supplied to Al-Indonesian and Al-Aqsa Hospitals, but still cannot 
perform cardiac examinations according to absent of cardiac options in these machines. 
1.7.7 Evolution of Catheterization in Gaza Strip  
The first of cardiac catheterization department was opened in 2006 at Gaza European 
Hospital, which is directed by the MoH and serves about 1.7 million people. The second 
catheterization center was also at Gaza European Hospital in 2013 funded from the Islamic 
Development Bank-Jeddah with implementation from the Qatar Red Crescent and the 
WHO. In 2014, the opening of a new catheterization department at Al-Shifa medical 
complex funded by the Qatar Red Crescent. Thus, there are three cardiac catheter devices 
in MoH hospitals. Moreover, there is four cardiac catheterization centers; two centers in 
the private sector (Jules Center and life Center), and two centers in non-governmental 
organizations (Public Aid Hospital and Al Quds Hospital).  
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1.7.8 Cardiac Catheterization services in the Gaza Strip  
In 2017, the number of diagnostic cardiac catheterization cases in the Gaza Strip was 2534 
distributed as 1347 at Al-Shifa hospital and 1187 at Gaza European Hospital. 
Approximately 41% of these cases had neither CAD nor non-obstructive CAD and advised 
to be followed by medical treatment. In contrast, 59% of cases had significant CAD 
managed with intervention percutaneous coronary intervention (PCI) or coronary artery 
bypass graft (CABG). Semi-annual report for 2018 indicates that the number of diagnostic 
cardiac catheterization cases was 906 cases (Al-Shifa records, 2018). 
1.8 Operational definitions 
1.8.1 Significant coronary artery disease 
Significant CAD is defined as more than 50% angiographic diameter stenosis in one or 
more of the epicardial coronary arteries. Based on disease severity, obstructive CAD is 
classified as single, double, or triple vessel disease (Gauchan et al., 2012; Niccoli et al., 
2015). In this study, significant CAD has defined as obstruction ≥ 50% stenosis of any 
coronary arteries, graft stenosis and stent restenosis. 
1.8.2 Coronary artery disease prevalence 
Prevalence is the probability of having the disease, also called the pretest likelihood of 
disease. The likelihood is a given test result would be expected in a patient with the target 
disorder and used to assess how good a diagnostic test to help in selecting an appropriate 
diagnostic test. Moreover, means the probability of a patient having the CAD before a 
diagnostic test result is known (Patterson et al., 1984; Patterson et al., 1995; Dorenkamp et 
al., 2012). In the current study, we used these definitions in the classification of CAD 
prevalence in the present study. 
 
10 
 
1.8.3 Coronary computed tomography angiography 
Coronary computed tomography angiography is a diagnostic imaging test that uses MSCT 
scanner to non-invasively image the coronary arteries of the heart. CCTA has become an 
integral imaging modality in the evaluation of CAD, facilitated by dramatic technological 
advances in the last decade, which has resulted in consistent acquisition of high quality 
images of the coronary arterial lumen as well as the wall with high accuracy and relatively 
low radiation doses (Yerramasu et al., 2010; Aghayev et al., 2016). In the current study, 
CCTA was performed through Phillips128 MSCT which have coronary imaging options. 
1.8.4 Invasive coronary angiography 
Invasive coronary angiography is the most accurate method (the "gold standard") for 
evaluating and defining CAD. Invasive coronary angiography is used to identify the exact 
location and severity of CAD. In contrast, it is an invasive test that allows a direct view of 
the coronary arteries supplying the heart.  
1.8.5 Effectiveness of diagnostic tests of CAD 
In the current study, the definition of effectiveness is based on the ability of a diagnostic 
test to accurately identify a patient with CAD. We also used  other definition in terms of 
the clinical outcome for patients enduring the examinations, that is, an increase in the 
number of quality-adjusted life years for a patient over a 10 year follow-up period (McNeil 
et al., 1975; Patterson et al., 1984; Patterson et al., 1995; Dorenkamp et al., 2012). 
1.8.6 Cost-effectiveness analysis 
Cost-effectiveness analysis provides a framework upon which to compare different 
management approaches through the prism of maximizing health benefit within the 
restriction resources (Weinstein and Stason, 1977). In the current study, cost-effectiveness 
is the ratio between the cost of an investigation and the proportion of test effectiveness. A 
decrease in cost per correct diagnosis indicates improved cost-effectiveness. 
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Chapter 2: Conceptual framework and literature review 
2.1 Conceptual framework  
The current chapter describes the mechanism of research steps in terms of choice of the 
nature of the cases that studied who have undergone CCTA and the cases that have 
undergone ICA as shown in figure 2.1. At that point, estimation the cost of both procedures 
with comparing the cost-effectiveness with drawing conclusions and provide a clear vision 
of the good use of resources to serve the delivery of health care at the lowest cost and best 
quality for the patient. 
 Coronary artery disease diagnosis 
Although ICA has been the gold standard for evaluating CAD, it should not be routinely 
performed as an initial test to assess CAD as indicated by the recent guidelines. The role of 
CCTA for evaluation of CAD becomes of great promise with high diagnostic accuracy. In 
the current study, the researcher focused on the diagnosis of the CAD with a utilization of 
the two modalities (ICA and CCTA). 
 Accuracy of CCTA 
The sensitivity, specificity, positive predictive value and negative predictive value of 
CCTA signify the diagnostic accuracy of CCTA for correct diagnosis of the CAD. The 
researcher measured the accuracy through the patients who underwent CCTA then they 
followed by ICA as a reference to more assessment or interventions. 
 Cost effectiveness analysis  
In the current study, we compare the cost-effectiveness of two diagnostic approach (CCTA 
and ICA) in the diagnosis of the presence or absence of CAD. The cost-effectiveness 
analysis was measured by performing a mathematical model based on Bayes' theorem and 
published clinical data was constructed to make these comparisons. This model permits 
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varying the values of data that are very difficult to obtain, such as the rates and costs of 
complications due to diagnostic procedures or due to CAD in particular patient groups. 
 Cost analysis 
Detailed activity-based cost analyses of the two modalities were carried out based on direct 
cost and induced cost. Direct cost includes the total cost of each modality including the 
cost of equipment, personal salary and procedure requirements and supplies. Induced cost 
is derived from the complications and mortality resulting from each test, as well as from 
the complications and mortality resulting from CAD that is inadequately treated because of 
false negative test results. 
  Effectiveness 
Effectiveness was defined as either the number of patients with CAD correctly diagnosed 
or as the number of quality-adjusted life years extended by therapy after the diagnosis of 
CAD. 
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Figure 2.1:  Conceptual framework of the study (self-constructed) 
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2.2 Literature review 
This part describes the previous related studies in respect to the efficiency and cost-
effectiveness of CCTA which perform through MSCT in the diagnosis of suspected CAD. 
The review of literature illustrated and has displayed with emphasis since 2004. Starting 
from this date, several studies were conducted on MSCT to replace ICA due to its non-
invasive nature and short time scanning. MSCT has been developing rapidly in recent 
years starting from 4-slice machines in 1998 up to 320-slice in 2007. The developing of 
MSCT exhibits many benefits particularly in reducing exam time and dose for patients 
likewise consequently to health providers. The high sensitivity of MSCT avoids the costs 
of unnecessary ICA in those referred for investigation CAD, mainly who don't have 
significant CAD. 
2.2.1 Accuracy of CCTA in the detection of CAD compared with ICA  
Our review of the literature identified a growing number of studies examining the 
usefulness of MSCT in a clinical setting. Increasing the number of slices in MSCT clearly 
confers benefits in terms of improved image quality and diagnostic accuracy for the 
detection of the significant CAD. In particular, it makes the imaging of smaller vessels 
more robust, allowing assessment of potentially the whole coronary circulation (Peebles, 
2006; Ostrom et al., 2008; Khan et al., 2009). 
Another study was done by Hausleiter et al. (2006) on patients with an intermediate risk of 
the CAD. The study evaluated the presence of coronary calcifications, non-calcified 
plaques, and lumen narrowing. With the use of 64 MSCT, clearly discernible non-calcified 
atherosclerotic coronary plaques can be detected in a large group of patients with an 
intermediate risk for having CAD. The assessment of these plaques by CCTA may allow 
for improved cardiovascular risk stratification. Hausleiter et al. (2007) conducted a 
prospective study to assess the clinical usefulness of CCTA for the detection of significant 
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CAD in patients with risk of having CAD. ICA was used as a reference. Based on the high 
negative predictive value observed, Hausleiter et al. suggested that CCTA could be a 
suitable means for the management of patients with an intermediate pre-test likelihood of 
significant CAD. Gaemperli et al. (2008), obtained a close result which showed a very high 
negative predictive value for reducing the need for ICA. These results agree with the 
literature review conducted by Delgado and Williams (2010) to confirm the diagnostic 
accuracy for CAD of MSCT in comparison to ICA.  
A comparison study was done by Meijboom et al. (2007) between CCTA and ICA was 
achieved on the groups at three levels: patient-by-patient, vessel-by-vessel, and segment-
by-segment analysis. Based on their results, Meijboom et al. found that the pretest 
probability of CAD influences the diagnostic performance of CCTA. Negative CCTA can 
reliably rule out the presence of significant CAD in symptomatic patients with a low or 
intermediate estimated probability of having significant CAD. A similar study by Husmann 
et al. (2008) evaluated patients with suspected CAD to compare the diagnostic accuracy of 
CCTA in groups of patients with low, intermediate, and high risk of CAD events. 
Husmann and his colleagues stated, ―Our data suggest that in a clinical setting, CTA would 
have avoided unnecessary invasive angiography in 56%, 41%, and 24% of patients in the 
groups with low, intermediate, and high risk for CAD events”. These results support a 
distinguished study performed by Budoff et al. (2008). Importantly lies that the 99% 
negative predictive value at the patient and vessel level establishes CCTA as an effective 
noninvasive an alternative to ICA to rule out significant CAD. 
Janne d‘Othée et al. (2008) performed a systematic review of the diagnostic accuracy of 
CCTA. The study illustrated how CCTA relates to the non‐invasive detection of coronary 
artery stenosis as an alternative to ICA. They included forty‐one articles published that 
evaluated native coronary arteries for significant stenosis and used CCTA as a diagnostic 
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test and ICA as a reference standard. The study settled that the diagnostic accuracy of 
CCTA is high. The advances in MSCT technology have resulted in an increase in 
diagnostic accuracy and proportion of assessable coronary segments. However, per patient, 
accuracy may be lower and CCTA may have more limited clinical utility in populations at 
high risk for CAD. Competitive a systematic review and meta-analysis reported by Mowatt 
et al. (2008a) concluded that given the high sensitivity and negative predictive value, the 
main role of CCTA may be to rule out significant CAD and reduce the need for ICA.  
The appropriate diagnosis of chest pain remains a difficult task in the emergency 
department (ED). Patient care for chest pain workup requires multiple imaging tests. The 
serial tests increase the length of the hospital stay and accumulate costs. In response to 
these problems, CCTA has become helpful in the ED setting. In a prospective 
observational cohort study, Hoffmann et al. (2006) found that 64-MSCT coronary 
angiography accurately distinguished a subset of patients with chest pain who could be 
safely sent home from the emergency department. In order to safeguard appropriate 
treatment following CCTA, controlled reporting among health providers is critical for the 
implementation of CCTA. Several studies, confirm that CCTA has been shown in low-risk 
populations to increase the rate of discharge from the ED, decline the length of hospital 
stay, increase the rate of detection of CAD, and reduce costs when compared to the current 
standard of care (Schlett et al., 2011; Litt et al., 2012; Cury et al., 2013; Poon et al., 2013; 
Hamilton-Craig et al., 2014). 
Coincide with evolution MSCT, a study done by Dewey et al. (2009) showed the 
diagnostic accuracy and less radiation exposure of 320 MSCT compared with cardiac 
catheterization. The use of emerging technology has the potential to significantly less 
vulnerable to suboptimal heart rate control and allow image acquisition with lower 
radiation and contrast doses compared with ICA while maintaining high diagnostic 
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accuracy. This is confirmed by meta-analysis research by Von Ballmoos et al. (2011) 
reviewed studies comparing CCTA results with ICA in symptomatic patients with 
suspected CAD. The analysis found early evidence suggests low-dose CCTA matches the 
sensitivity of ICA, has low radiation exposure, and is a potentially valid alternative to 
catheter angiography for triaging symptomatic patients with a clinical suspicion of the 
CAD. Correspondingly study by Uehara et al. (2013), supported the result of diagnostic 
accuracy of 320 MSCT for detection of significant coronary artery stenosis in patients with 
various heart rates and heart rhythms, compared with ICA. 
A study was done by Sajjadieh et al. (2013) evaluated the accuracy of CCTA in 
comparison to ICA in the diagnosis of significant stenosis (≥50%) of the coronary artery 
tree. The findings of this study revealed that CCTA with 64 MSCT could be considered as 
a suitable technique for rapid triage of patients presenting to hospitals with chest pain. 
Inference, the ability of CCTA is obvious to combine anatomical and physiological cardiac 
evaluation in a single examination is a promising new technique that can provide further 
optimization for the assessment of patients with suspected or known CAD.  
Review article conducted by Alani and his colleagues (2014) to visualization the 
improvement in CCTA diagnostic accuracy. This review article summarizes CCTA has 
been a reliable noninvasive imaging test that can substantially contribute to the assessment 
of CAD with high diagnostic accuracy, guiding clinical decisions in patients with low to 
intermediate pretest likelihood of CAD. 
The accuracy of CCTA was also checked by Joshi et al. (2016) compare ICA in patients 
undergoing major non-coronary cardiac surgeries regarding true positive and true negative 
values. The overall sensitivity and specificity of CCTA was 100% and 91.30%. The 
positive 50% and negative predictive values 100% of CCTA were also high in these 
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patients. The study suggests that this non-invasive technique may improve pre-operative 
risk stratification in patients undergoing non-cardiac surgery. 
A randomized controlled trial conducted by Dewey et al. (2016) to evaluate whether ICA 
or CCTA should be performed in patients clinically referred for ICA with an intermediate 
probability of CAD. The search is ongoing for a gatekeeper that will reliably exclude 
normal ICA. This randomized trial revealed that patients with atypical symptoms 
suggestive of CAD, CCTA carefully delayed ICA with no increase in long-term events, 
reduced minor but not major procedural complications compared with direct ICA and 
shortened the length of hospital stay. CCTA was associated with reduced ICA rates and 
increased the diagnostic yield of this procedure but did not reduce exposure to radiation.  
Bayar and Feng (2017) assessed the analytic precision of CCTA as a different option for 
ICA in evaluating CAD. This review study selected 57 patients, who experienced both ICA 
and additionally CCTA. The study confirmed that CCTA has high accuracy in detection 
CAD. Moreover, the study settled that indicative precision of MSCT was found to be 
higher in moderate and extreme stenosis and can be utilized as a substitute to ICA. 
Recent interest in fractional flow reserve (FFR) measurements derived from computed 
tomography (CT-FFR) to evaluate the degree of coronary stenosis. Various studies have 
been performed comparing the diagnostic performance of CT-FFR to invasive coronary 
angiography fractional flow reserve (ICA-FFR). Parekh et al. (2017), analyzed studies 
comparing CT-FFR to ICA-FFR. Regarding this search, CT-FFR has high sensitivity and 
negative predictive value when compared to ICA-FFR. However, improvements are 
needed to increase the specificity and positive predictive value. A parallel study conducted 
by Kueh et al. (2017) which revealed that FFR derived from CCTA has been shown to 
have excellent correlation with invasive FFR with robust of guiding CAD patients.  
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2.2.2 Preference of MSCT in illustration of coronary artery anomalies compared to 
ICA 
Early identification of an anomalous coronary anatomy is quite relevant to identify variants 
without clinical relevance to avoid complications during surgery or angioplasty can occur. 
For several decades, premorbid diagnosis of coronary artery anomalies has been made with 
ICA. However, this imaging technique has limitations due to its projections and cannot 
always adequately provide the required information about the abnormal coronary anatomy. 
CCTA is robust that has several clinical applications. It not only provides high-resolution 
anatomical information of the coronary artery tree but also helps define other aspects of the 
cardiovascular anatomy. 
Reviewing CCTA studies by Budoff et al. (2006b) showed the clinical role played by 
CCTA in the evaluation of different types of coronary arterial anomalies. The results of 
this review support the use of CCTA as a safe and effective noninvasive imaging modality 
for defining coronary arterial anomalies in an appropriate clinical setting, providing 
detailed three-dimensional anatomic information that may be difficult to obtain with ICA.  
Obvious advantages were recorded in delineating coronary arterial anomalies and for 
obtaining an accurate diagnosis for formulating an optimal patient treatment plan. Finally, 
the results of these studies support the use of CCTA as a harmless and effective 
noninvasive imaging modality for defining coronary artery anomalies in an appropriate 
clinical setting, providing comprehensive anatomic information that may be challenging to 
attain with ICA (Coles, 2004; Schmitt et al., 2005; Kim et al., 2006; Kang et al., 2008; 
Srinivasan et al., 2008; Van Mieghem and De Feyter, 2009; Fadhil, 2012; Qin et al., 2012; 
Javoran, 2013; Graidis et al., 2015). 
A retrospective study has been done by Yorgun and his colleagues (2010) to evaluate the 
efficiency of CCTA in the diagnosis of coronary artery fistulas. The study exhibited that 
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CCTA is an excellent tool with brilliant efficiency for visualization the origin, course, and 
drainage site of coronary artery fistulas. 
ICA has traditionally been indicated to demonstrate the coronary vasculature in detail and 
has remained the reference standard imaging modality. Owing to the potentially complex 
three-dimensional anatomy of the coronary anomaly, ICA not infrequently, incompletely 
delineates the anatomical course of the coronary anomaly. Qin (2015) conducted a study 
sought to determine the ability of MSCT to detect the origin and course of the anomalous 
coronary artery. This study confirmed that CCTA is essential detecting method to find 
coronary anomalies and MSCT clearly depict the origin and course of the anomalous 
coronary artery. 
Recently, a retrospective study on 974 patients who underwent CCTA for detection of 
coronary anomalies was done by Prasad and Vijayakumar (2017). The study approved that 
regardless of the complexity of the vascular anatomy, coronary vessel opacification is 
always possible by CCTA. Additionally, CCTA is an accurate non-invasive imaging 
modality which suitable to evaluate patients that have an anomalous coronary artery, 
especially when they have symptoms relating to anomalous vessels. 
2.2.3 Assessment of coronary artery stent patency and restenosis using MSCT with 
compare to ICA 
Surveillance ICA is recommended after stent supported PCI due to the unpredictable 
occurrence of in-stent restenosis. The efficacy of MSCT to assess coronary stent stenosis 
was approved by several studies, but there was debated in their results. To be specific, 
increasing the developing of MSCT give more accuracy in evaluation of the stent. The 
Studies supporting the value of MSCT indicating that CCTA may be most valuable as a 
noninvasive method of excluding coronary stent stenosis. In additionally, advanced options 
in MSCT such as luminal density analysis increase it is ability to display the stent lumen 
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clearly and is extremely helpful for patient follow-up (Cademartiri et al., 2007; Oncel et 
al., 2007; Sun and Almutairi, 2010; Zhao et al., 2011; Bharati et al., 2012; Dighe et al., 
2012; Geyer et al., 2015; Dawoud et al., 2016; Moradi et al., 2017). 
In contrast, different studies upset these results and despite the tremendous improvements 
in MSCT, and still indicate relevant limitations of CCTA imaging of coronary artery 
stents. These studies settle that the value of CCTA with of coronary stents depends on 
patient and stent characteristics with a large diameter. Due to these limitations, use of 
CCTA for evaluation of in‐stent restenosis is not considered for routine clinical use. Thus, 
patient selection is crucial for success (Mahnken et al., 2006; Maintz et al., 2008; Mark et 
al., 2010; Yang et al., 2012; Windecker et al., 2015).  
2.2.4 Diagnostic value of MSCT angiography in the comprehensive assessment of 
CABG compared to ICA 
Plentiful studies undoubtedly pointed that CCTA has high diagnostic accuracy in the 
proper evaluation of the patency of CABG cases compared with ICA and even with a more 
brilliant performance than an assessment of native coronaries. This superior diagnostic 
accuracy may be due to the grafts naturally consider less motion through the cardiac cycle 
than native coronary vessels, larger vessel diameter of grafts, and lower tendency to 
develop calcified plaques compared with native coronaries. The modernist technological 
development of 64 MSCT enables the noninvasive assessment of venous and arterial 
bypass graft patency and stenosis with high diagnostic accuracy even in patients with 
arrhythmias during scanning. Furthermore, CCTA is more effective in the evaluation of 
bypass grafts as compared to heavily calcified native coronary arteries. CCTA is a 
relatively painless noninvasive procedure when compared to ICA, and it is well tolerated 
by most of the patients. CCTA can represent a convenient noninvasive method for 
diagnosis of coronary artery stenosis in CABG patients with a higher diagnostic accuracy, 
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being greater than of native coronary arteries, and the advantage of visualizing grafts that 
cannot be detected or accessed by ICA. Evaluation by ICA in patients with prior CABG 
can be challenging and expose patients to rare complications such as injury to the graft 
vessel during catheter engagement. Upstream CCTA has the possible to make ICA faster 
and more efficient due to an improved understanding of CABG anatomy prior to 
attempting to engage graft evaluation (Schlosser et al., 2004; Chiurlia et al., 2005; Meyer 
et al., 2007; Hamon et al., 2008; Chaosuwannakit et al., 2014; Pesenti-Rossi et al., 2014; 
Azizi et al., 2016; Barbero et al., 2016; Barbero et al., 2017; Eisenberg et al., 2017). 
2.2.5 Cost-effectiveness analysis of CCTA versus ICA 
Given the possible benefits of introducing an extensively accessible non-invasive option 
for CAD detection. The potential clinical and economic impact that broad adoption of 
CCTA would have on systems of care, and the uncertainty over the evidence on the net 
health benefits and appropriate use of CCTA. All healthcare decision makers will benefit 
from a formal appraisal of the comparative clinical effectiveness and comparative value of 
CCTA for diagnosis of the CAD. 
Cost-effectiveness of CCTA and MRI according to the prevalence of CAD compared with 
the gold standard ICA was studied by Dewey and Hamm (2007). Their outcomes coincided 
that CTCA has good cost-effectiveness up to a prevalence of 60%–70%, whereas ICA is 
more cost-effective in patients with higher prevalence. For patients with a 10% to 50% 
pretest likelihood of CAD, CCTA was the most cost-effective approach, with costs per 
correctly identified CAD patient of 4,435 euro (10% likelihood) to 1,469 euro (50% 
likelihood). ICA to be most cost-effective for a pretest likelihood of at least 70%, with 
costs per correctly identified CAD patient ranging from 1,153 euro (70% prevalence) to 
807 euro (100% prevalence). 
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In a distinct study, Mowatt et al. (2008b) reported the clinical effectiveness and cost-
effectiveness of the CCTA as an alternative to ICA for the investigation of the CAD. They 
found the main value of CCTA through 64 MSCT to be ruling out significant CAD. A 
negative CCTA for CAD should avoid the costs of unnecessary ICA, thus resulting in 
overall cost savings in the diagnostic process of the CAD. However, it is unlikely to 
replace ICA in the assessment of revascularization cases.  
Kreisz et al. (2009) execute a study to evaluates the cost-effectiveness of 64-slice CTCA as 
an alternative to ICA in an elective outpatient setting for patients otherwise referred to 
ICA. The results indicate that CTCA is a cost-saving approach contribution a higher 
health-related quality of life up to approximately 65% pre-test risk of the CAD. Above that 
threshold, their model predicts a cost-utility trade-off with every gain in health-related 
quality of life through the use of CTCA as a rule-out test being associated with additional 
costs when compared to ICA. The health economic analysis of their study predicted that 
CCTA to be a cost-effective approach in symptomatic patients at low to intermediate risk 
of significant obstructive CAD otherwise referred to ICA. 
A comparable study was done by Stacul et al. (2009) to analyze the costs of 64 MSCT 
CCTA compared to ICA and to determine the cost-effectiveness of the two modalities. 
Detailed activity-based cost analyses of the two modalities were carried out at the 
departments of radiology and cardiology. The differential costs (equipment, variable, 
personnel), common costs and external costs were estimated. The sum of differential costs, 
common costs, external costs and hospitalization costs provides the full cost for each 
examination. The cost of ICA procedure was approximately 9 times of CCTA procedure. 
In particular, the cost of ICA was 2,027.88 euro versus 230.03euro for CCTA procedure. 
Cost-effectiveness analysis showed that the cost per correctly identified CAD patient 
decreased exponentially with increasing pretest likelihoods (prevalence) of CAD. CCTA 
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was more cost-effective than ICA up to a prevalence of 86%, with a cost per correct 
diagnosis of CAD ranging from 7,295.10 euro (10% prevalence) to 2,593.9 euro (86% 
prevalence). By contrast, ICA shows better cost-effectiveness for a prevalence of 87%–
100%, with a cost per correct diagnosis of CAD between 2,563.59 euro (87% prevalence) 
and 2,207.60 euro (100% prevalence). This study approved that CCTA has far lower costs 
than ICA, and its cost-effectiveness is better in the large majority of patients. 
Decision tree analysis to determine the cost-effectiveness and radiation dose that would 
result from performing CCTA before ICA employed by Halpern et al. (2010). In their 
study, they reported that cost reduction with CCTA depends on the prevalence of CAD, but 
overall costs are reduced as long as the prevalence is less than 85%. At a 50% prevalence 
of CAD, performing CCTA before ICA results in an average cost saving of 789 dollars per 
patient with a false-negative rate of 2.5% and average additional radiation exposure of 1–2 
mSv. The analysis illustrated that performing CCTA before ICA is a cost-effective strategy 
in the care of patients without symptoms who have positive stress test results when the 
probability that the patient has significant CAD is less than 50%. The false-negative rate 
with this strategy compares favorably with the false-negative rate of stress testing. Thus, 
the use of CCTA in asymptomatic patients with this role can avoid unnecessary ICA 
procedures. 
Direct costs and comparative cost-effectiveness of new generation MSCT (dual-source CT) 
and ICA for diagnosing the CAD measured through Dorenkamp et al. (2012). Cost 
calculations were based on a detailed analysis of direct costs. Based on Bayes‘ theorem, a 
mathematical model was used to compare the cost-effectiveness of both diagnostic 
approaches. Total costs included direct costs, induced costs and costs of complications. 
Effectiveness was defined as the ability of a diagnostic test to accurately identify a patient 
with CAD. The study resulted that direct costs amounted to 98.60 euros for CCTA and 
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317.75 euros for ICA. Analysis of model calculations indicated that cost-effectiveness 
grew hyperbolically with an increasing prevalence of CAD. Given the prevalence of CAD 
in the study cohort (24%), CCTA was established to be more cost-effective than ICA (970 
euros versus 1354 euros) for one patient correctly diagnosed as having CAD. At a disease 
prevalence of 49%, CCTA and ICA were equally effective with costs of 633 euros. Above 
a threshold value of disease prevalence of 55%, proceeding directly to ICA was more cost-
effective than CCTA. According to their outcomes, with appropriate patient selection and 
consideration of disease prevalence are critical for the direction of the patient to the best 
diagnosis. While ICA remains the gold standard for diagnosing CAD, prudently achieved 
CCTA may be an economically efficient substitute to ICA, especially in ruling out CAD in 
patients with an intermediate pretest likelihood. 
A study with a wonderful perspective combines tangled aspects of human life conducted 
by Gorenoi et al. (2012). The researchers evaluated the clinical efficacy, diagnostic 
accuracy, prognostic value cost-effectiveness as well as the ethical, social and legal 
inferences of CCTA versus ICA in the diagnosis of the CAD. The result of this study from 
a medical point of view, CCTA using at least 64 MSCT should be recommended as a test 
to rule out significant CAD in order to avoid inappropriate ICA in patients with an 
intermediate pretest probability of CAD. From a health economic point of view, this 
recommendation should be limited to patients with a pretest probability of CAD of 50% or 
lower. From a medical and health economic point of view, neither CCTA nor ICA may be 
recommended as a single diagnostic test for identifying or ruling out functionally relevant 
coronary stenosis. To diminish any potential negative ethical, social and legal insinuations, 
the general ethical and moral values of benefit, autonomy, and justice should be 
considered. 
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A study by Catalán et al. (2013) explored the cost-effectiveness of two alternative 
strategies to rule out significant CAD in the pre-operative evaluation of non-coronary 
cardiovascular surgery. The study concluded the initial CCTA strategy for the pre-
operative evaluation of non-coronary cardiovascular surgery in experienced groups 
represents not only a more comfortable diagnostic strategy for the patient but is also more 
cost-effective than the ICA strategy. It produces a saving of 411euro per patient as well as 
a benefit due to the possibility of avoiding potential complications and post-ICA death. 
Randomized trials conducted by Hlatky et al. (2013) to reconsideration the projected costs 
and consequences of CCTA. These randomized trials have shown that FFR guided PCI 
improves clinical outcome and reduces costs compared with visually guided PCI. FFR has 
been measured during ICA, but can now be derived noninvasively from CCTA images 
(FFRCT). Consequences of these trials, the projected initial management costs were 
highest for the ICA visual strategy (10702 dollars), and lowest for the FFRCT strategy 
(7674 dollars). A strategy of using FFRCT to guide the selection of patients for ICA and 
PCI might reduce costs and improve clinical outcomes in patients with suspected CAD. 
Respecting to cost-effectiveness matching with test accuracy, a study was achieved by 
Malagò et al. (2013). The study revealed a proper diagnostic protocol for patients with 
suspected CAD by the introduction of CCTA. According to the cost-effectiveness analysis 
based on their data, CCTA costs about 230.03 euro, whereas ICA costs about 1,551 euro. 
Cost-effectiveness analysis confirmed how the costs for correctly categorizing a patient 
with CAD decrease significantly as the pretest probability increases. CCTA has a better 
cost-effectiveness ratio compared with ICA on condition that the pretest probability is 
<86%, which resembles low to intermediate risk patients. The study confirmed the greater 
diagnostic performance of CCTA compared with the stress test and its similar accuracy to 
ICA. The use of CCTA to select patients for ICA has a favorable cost-effectiveness profile. 
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The costs and cost-effectiveness of CTCA in comparison with ICA for the diagnosis CAD 
from the point of view of the healthcare provider were studied by Darlington et al. (2014). 
The average cost of CTCA was estimated to be 180 euros based on the use of a 64MSCT 
with comparison1,378 euros cost of ICA. The incremental cost-effectiveness ratio is 6,380 
euro for each additional correct diagnosis that would be attained with ICA strategy 
compared to a triage strategy with CCTA that excludes negative CCTA from further 
testing. A strategy of CTCA triage in the intermediate-risk group, no imaging test in the 
low-risk group, and ICA in the high-risk group, has good diagnostic accuracy and could 
significantly cut costs.  
The cost-effectiveness of seven coronary diagnostic strategies was assessed through a 
study implemented by Ferreira et al. (2014). The cost-effectiveness of each strategy was 
defined as the cost per correct diagnosis (inclusion or exclusion of significant CAD) in an 
asymptomatic patient. This study of great importance has been proved widely clinical 
assessment of an individual with suspected stable CAD is usually complemented by 
noninvasive tests. Furthermore, the diagnostic algorithms that include CCTA are the most 
cost-effective in symptomatic patients with suspected stable CAD and a pretest likelihood 
of disease of ≤50%. In these patients, depending on the pretest likelihood of disease and 
the willingness to pay per correct diagnosis, CCTA may be used as a first-line test or 
reserved for patients with positive or inconclusive results. In high-risk patients, immediate 
ICA appears to be the most cost-effective strategy. 
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Chapter 3: Methodology 
This chapter provides comprehensive information about all aspects of research methods 
and addresses issues related to the methodology that used to achieve the research 
objectives. It explains the study design, study populations, the setting of the study, period 
of the study, eligibility criteria, data collection methods, statistical analysis, piloting, and 
validity of the instruments. In addition, it clarifies the ethical considerations and the 
limitations of the study as well. 
3.1 Study design 
The design of this study is triangulated observational, analytical, a prospective study 
carried out among the patients with suspected CAD and also for evaluation CAD patients 
(grafts or stent) to investigate accuracy in recurrent ischemic symptoms who underwent 
CCTA and ICA. Analytic research generates new knowledge about concepts and identifies 
relationships between variables (Burn and Grove, 2001). The prospective studies refer to 
the likely prevalence of a phenomenon, situation, problem, attitude or outcome in the 
future. Such studies attempt to establish the outcome of an event or what is likely to 
happen (Kumar, 2011). Within the context of this study, the prospective cohort will allow 
the researcher to follow up cases that with risk CAD and underwent diagnosis with ICA or 
CCTA over the study period of time. 
In the current study, methodological triangulation would provide combination between 
quantitative and qualitative paradigms to validate findings from one method with another, 
or to enhance understanding of the facts on the ground (Donovan and Sanders, 2005). 
Qualitative paradigms are humanistic because it focuses on the personal expert, focused 
data, and experiential basis of knowledge and practice. It is also holistic because it seeks to 
situate the meaning of particular behaviors and ways of thinking about or doing things in a 
given context (Kielmann et al., 2011).  
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The cost-effectiveness analysis was carried out by using an adaptive mathematical model 
to assess the relative cost-effectiveness of CCTA imaging and ICA. The accuracy of 
diagnostic test characteristics of CCTA (sensitivity and specificity) obtained by following 
the patients with suspected CAD who underwent CCTA and then they were followed by 
ICA. 
3.2 Study setting 
The study was carried out in the main governmental hospital in the Gaza Strip. In 
particular, the study was carried out at the cardiac catheterization and computed 
tomography departments at Al-Shifa hospital. 
3.3 Study population 
The study includes two types of the population who were represented the quantitative and 
qualitative parts. 
 Quantitative part: the current study comprises three patient populations. The first 
target is patients presented with a suspected risk of CAD underwent CCTA. The 
second target is patients presented with a suspected risk of CAD underwent ICA. The 
third target is patients underwent CCTA then followed up by ICA.   
 Qualitative part: this part involved a group of key specialists who are involved in 
diagnosis CAD during the period of the study. This was interesting and enhancing our 
study to be more valuable and interpreted some results according to their experiences. 
3.4 Eligibility criteria  
3.4.1 Inclusion criteria: 
 Patients providing written informed consent and willing to participate. 
 Non-urgent patients with appropriate preparation for both procedure. 
 Patients presenting with suspected CAD underwent CCTA and ICA. 
 Patients underwent CCTA then followed by ICA.  
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 Patients with a history of CABG referral for following up. 
 Patients with a previous history of PCI to rule out stent restenosis. 
3.4.2 Exclusion criteria: 
 Emergency patients diagnosed by ICA or CCTA. 
 Pediatric patients who presented for assessment cardiac morphology. 
 Patients have contraindications to CCTA (Heart rate ≥ 65 beats per minute and 
contraindication for beta blockers or nitroglycerin drugs). 
 Patients with a history of severe allergy to an iodinated contrast agent. 
 Patients with impaired kidney function or under dialysis. 
 CCTA with poor image quality (poorly visualized coronary segments). 
3.5 Study period  
The study lasted 20 months executions; it started in March 2017 and completed by October 
2018. The research proposal has been submitted to defend in the front of the school of 
public health assigned a committee in May 2017. Initially, the research proposal described 
the entire process and provided information about study design, data collection, and 
analysis methods and tools. After obtaining the committee's approval, the researcher 
prepared the required tools for this study. The tools were arbitrated by experts and their 
opinions were taken into considerations. The researcher has consulted a group of 12 
experts (two consultant cardiologists, three consultant radiologists, four public health 
consultants, two medical imaging specialist, and one decision maker at MoH). The 
arbitration stage lasted for six weeks including the refining of tools in the light of 
reviewers and the academic supervisor‘s feedback. In August 2017, the tools were ready to 
start the data collection and the researcher trained two data collector and carried out the 
required training prior to piloting and fieldwork. Piloting conducted between 1 and 30 
September 2017. Initially, the study constructed to be retrospective, but challenges in data 
31 
 
collection, as incomplete the patient files and limited information about both procedures 
pushed us to make it as a prospective study. Consequently, the study reconstructed to be 
prospective and followed up the patients from the appointment period through the final 
diagnosis. Another piloting was performed and actual data collection of quantitative part 
and data entry as well started on 2
nd
 January through 30 June 2018. Data entry was 
performed daily in parallel with data collection. Analysis part of the study was 
immediately initiated after the completion of data collection. Data management and 
recoding of variables were done, descriptive analysis and frequency tables were extracted, 
and then inferential statistics were performed. The accuracy of CCTA was checked and 
cost-effectiveness analysis model constructed/adopted to appropriate the study objectives. 
The researcher started to prepare the final report which has been finalized by October 
2018. 
3.6 Sample size and sampling process 
3.6.1 Quantitative part  
The sampling process flow chart illustrated in Figure 3.1, which was done in three methods 
to appropriate the eligibility criteria as follows:  
1. Census Survey 
The aim of selecting this sample study is to study all patients who underwent CCTA well-
matched with study inclusion criteria. The sample size was 131 patient who optimal 
imaged by CCTA during the study period.  
2. Purposive (Typical Case Sampling) 
Typical case sampling is a type of purposive sampling useful when a researcher wants to 
study trend as it relates to what is considered typical members of the affected population. 
In the current study, about 58 patients imaged by CCTA then referred to ICA were 
obtained to assess the accuracy of CCTA and added-values of ICA. From this sample, we 
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calculate the CCTA accuracy (sensitivity, specificity, positive predictive value, and 
negative predictive value of CCTA) considering the ICA as the golden stander reference of 
diagnosis patients with suspected CAD. 
3. Purposive Sample  
This sample was taken into account to explain some of the variables needed to determine 
the cost analysis. In order to calculate the sample size of the patients underwent ICA, 
Monkey survey online program was used and resulted in a sample size at least 241 cases 
for representativeness at 95% confidence interval and 5% margin of error (Annex 3). The 
researcher has taken into consideration the following parameters during the sample size 
calculation: 
 The total number of patients underwent ICA during the year 2017 was 1290 patients at 
Al-Shifa hospital (Al-Shifa records, 2017). The researcher estimated that the same 
number of the patient where have been undergone ICA during the year 2018 and half 
of them (645 patients) were diagnosed in the first half of the year 2018. 
 The program revealed that the required sample was 241 at confidence interval 95%., a 
margin of error 5%, and for more representation, the researcher increased the sample 
size by additional 9 participants to compensate non-respondents and also to increase 
the statistical power that the sample size reaches 250 patients.  
 From the 250 patients, we ensure that the 58 patients who referral from CCTA were 
included in this sample. 
 In order to establish the appropriateness of the sample size for the total number of 
patients, the number of patients who underwent ICA was obtained during this period. 
The number of patients was 609 based on the semi-annual records (Al-Shifa records, 
2018). 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Sampling process flow chart  
3.6.2 Qualitative part  
A purposive sample of seven different medical specialists involved in CAD diagnosis 
modalities was selected. The integration between quantitative and qualitative data is 
important to deeply interpretations related results and perspectives. The qualitative 
component was carried out after finishing the quantitative one in order to deeply explore 
important issues emerged from the quantitative part. 
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3.7 Study instruments  
 Quantitative part 
The data were collected by the researcher with the cooperation of trained health providers 
from Al-Shifa Hospital. To identify the characteristic of the two diagnostic modalities 
(ICA and CCTA). Two arbitrated questionnaires were constructed to translate research 
objectives (Annex 4 for CCTA, and Annex 5 for ICA); which covered the following 
areas: 
1. Demographic and personal information 
 Personal information as gender, age, weight, and height. 
 Personal habits as lifestyle and smoking. 
2. Medical history and previous cardiac procedures 
 Medical history and patients complain: Family history of heart disease, high 
cholesterol, high blood pressure, diabetes and chest pain). 
 History of cardiac medical intervention: Angioplasty/Stent or Balloon and CABG 
 Previous cardiac examinations: Resting Electrocardiography, Exercise Stress Test, 
Cardiac Echocardiography and Calcium Scoring Test. 
3. Variables for cost-effectiveness analysis 
Additionally, the questionnaire will also cover the differential variables that depend on the 
patient procedure (ICA or CCTA). These variables are essential for cost analysis and cost-
effectiveness analysis such as: 
 Pre-procedure preparation blood test such as: Complete Blood Count (CBC), kidney 
function such as Urea and Creatinine, hepatitis test such as hepatitis C virus (HCV) and 
hepatitis B virus (HBV), coagulation test such as Prothrombin Time (PT), Partial 
Thromboplastin Time (PTT), and International Normalized Ratio (INR). 
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 Drugs administration: preparation's drugs such as beta blockers drugs and sublingual 
nitroglycerin, and recovery drugs.  
 Variables during the procedure: Estimated radiation dose, supplies used during 
procedures and recovery period, staff procedure and contrast volume. 
 Potential complications: bleeding, allergy reactions, shock, and death. 
 The diagnostic result of both procedures and categorization of the diseased result to 
significant CAD ≥ 50% stenosis and non-significant CAD ˂ 50% stenosis. 
 Qualitative Part 
For the qualitative data, the researcher used open-ended (semi-structured) questions  
(Annex 6). Those questions were asked by the researcher within in-depth interviews with 
seven medical specialists working in CAD diagnosis field. The interviews focused on the 
diagnostic process and if there is available standard policy in referral and diagnosis of 
CAD, the role of imaging modality in the diagnosis, challenges to perform the optimal 
CCTA procedure and the view of the referring cardiologists in related to CCTA versus 
ICA.  
3.8 Ethical and administrative considerations 
An ethical approval was asked for from the School of Public Health at Al-Quds University 
and Helsinki Committee (Annex 7). Admin approval was obtained from the human 
resources development directorate general in the MoH (Annex 8). To guarantee patient 
rights, a covering letter indicating that the participation is voluntary and confidentiality 
was assured for all of the participants. Moreover, each participant received complete 
information and explanation about the research purpose, nature, and have a consent form. 
The researcher assumed that other ethical rights were protected through respect for people 
and respect for truth. 
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3.9 Pilot study 
Quantitative part: A pilot study included 30 suspected CAD patients who underwent the 
ICA and 15 suspected CAD patients who underwent the CCTA were done to explore the 
appropriateness of the study instruments and let the researcher train for data collection. The 
pilot study improved the study validity and reliability. As a result of this step, few 
rephrasing and explanation were added to some items in the questionnaire. 
Qualitative part: A pilot interview was done with a radiologist, cardiologist and medical 
imaging specialist which allowed for further improvement of the study validity and 
reliability. As a result of this stage; asking the questions was improved to be more deeply. 
3.10 Data collection technique  
After completing the pilot study, the researcher and two data collectors gathered the data 
from the cardiac catheterization and MSCT departments according to the inclusion and 
exclusion criteria. The researcher himself filled the questionnaire by reviewing the medical 
files for all participants. Furthermore, some items were filled through contact with medical 
staff during the procedure. In case of incomplete records, the researcher contacted the 
patients in order to bring the required reports. This stage was completed after 6 months. 
Training was done for the data collectors about the study objectives and vague questions 
were clarified. In the fieldwork, the researcher began to collect the data in order to help 
him assistants fully comprehend the questionnaire's items. To monitor the data collection 
process and make sure of the progress in the data collection, the researcher supervised 
every day according to his work as CCTA imaging specialist and the presence of the two 
departments in the vicinity. Confidentiality and privacy were taken into consideration. The 
CCTA procedure evaluated and reported by CCTA consultant and ICA procedure 
evaluated and reported by cardiologist consultant. The diagnosed cases sorted to estimate 
supplies and total cost of the procedure. 
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3.11 Scientific rigor 
3.11.1 Quantitative part (questionnaire) 
3.11.1.1 Validity 
Face validity: Questionnaires were organized in order to allow smooth data collection. In 
addition, the data were arranged sequentially in line with the tests under study. 
Content validity: Concerning the content validity, adequate reviewing of related topics in 
the literature about CEA, ICA, CCTA, and CAD were done before designing the study 
instruments and tools. To assess the relevance of the questionnaires, experts conducted the 
evaluation process (Annex 9), and comments were taken into consideration. Furthermore, 
the researcher reviewed some medical files prior to the study and check about the 
availability of study items. A validation data by identification number and coding number 
using to excel sheet was used to avoid duplication of cases. The researcher has 
incorporated experts‘ suggestions into the data collection tool. This would increase the 
validity of the questionnaire. 
3.11.1.2 Reliability 
The following steps were done to assure instruments reliability 
1. Standardization of filling the questionnaires. 
2. The data entry was filled in the same day of data collection would permit possible 
interventions to check the data quality or to re-fill the questionnaire when required. 
3. Re-entry of 5% of the data after finishing data entry was done to correct the entry 
procedure and decrease the entry errors.  
3.11.2 Qualitative part (in-depth interviews)  
To safeguard the trustworthiness of the qualitative part in the current study, three steps were 
considered. First, a peer check was completed by health experts to review in-depth interview 
questions to assure that they cover all the essential domains. Second, points were taken about 
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the important issues discussed during the interviews. Third, a debriefing report was written at 
the end of each interview including the most key points discussed during it. 
3.12 Data entry and analysis 
Quantitative part: The researcher used the Statistical Package for Social Science (SPSS 
version 21) program for data entry and analysis. The first stage of data entry was through 
constructing the entry base and coding of variables, followed by actual data entry. Data 
entry was performed at the time of data collection. At the analysis stage, data cleaning and 
data management for the variables of interest were performed. 
The management of data depended upon scientific literature, merging and discretizing 
continuous variables into categories with minimal loss of information. Descriptive analysis 
cross-tabulation was used to describe the main features of the data. Chi-square test to 
compare categorical variables. An independent t-test was used to measure the difference in 
means of normally distributed data between two independent groups. 
Logistic regression is a predictive analysis that used to explain the relationship between 
one dependent binary variable and one or more nominal, ordinal, interval or ratio-level 
independent variables. Simple logistic regression describes the univariable analysis which 
was used to select potential independent variables associated with the risk of the CAD. 
Multiple linear regressions were used to examine the association between risk of the CAD 
significant independent variables. and These findings were presented as a regression 
coefficient (B), an odds ratio (OR), a 95% confidence interval (CI) and a P value < 0.05. 
The diagnostic performance of CCTA for the detection of the CAD with ICA as the 
standard of reference was presented as sensitivity, specificity, positive and negative 
predictive values.  
Qualitative part: Open coding thematic analysis technique was used to analyze the 
transcripts of the in-depth interviews. The researcher would gain the main findings from 
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the interviews. Then, categorization of related ideas, comparison and integration between 
the quantitative and the qualitative findings was done to create rich items for discussion 
and interpretation.  
3.13  Cost analysis  
The researcher used the Excel program for cost analysis and cost-effectiveness analysis. 
Concerning the economic evaluation, the costs (in dollars) of both diagnostic approaches 
(CCTA and ICA) were recognized through a detailed analysis of all involved procedures. 
Total costs of a diagnostic modality included direct costs and induced costs (expected cost 
of complications).  
3.13.1 Direct cost 
Direct costs were classified into three categories: diagnostic-specific equipment costs, 
materials and supplies costs and personnel costs. Occupancy costs included heating, air-
conditioning, light, cleaning, insurance, furniture, security, secretarial and stationery 
requirements were considered fixed in both departments, so they were excluded from the 
cost calculation. 
3.13.1.1 Equipment costs 
Diagnostic-specific equipment cost included purchasing, repair, and maintenance. 
Installation contracts provided for a defects' liability period. Equipment purchase costs 
were obtained from the hospital administrative records. The utility of equipment also was 
taken into account by calculating the equipment lifetime per year divided on all conducted 
patients.  Equipment lifetime, for calculating amortization, was considered to be 10 years, 
which is the maximum technological lifespan of radiological equipment according to the 
European Society of Radiology (ESR) (ESR, 2014). Equipment repair identified in six 
months (the period of data collection). Maintenance and average annual interest payments 
costs were obtained from the hospital administrative records and purchases contracts 
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awarded to tender equipment. All items of equipment cost have been taken into 
consideration through the workload of each diagnostic method. Furthermore, we analyzed 
this cost by determining the total number of patients who performed any procedure during 
the study period. Finally, the cost per patient for each modality was calculated. 
3.13.1.2 Cost of materials and supplies 
Cost of materials and supplies reflected market prices paid to manufacturers and vendors. 
We calculated all supplies which need to perform the diagnostic procedure for each patient 
in the two modalities. The supplies consider as single use for one patient was calculated 
according to the price list. In another hand, the supplies which used for multiple patients 
were estimated by a factor for each patient. Contrast media which used to visualize the 
coronary arteries during the diagnostic procedure is varied according to patients, thus we 
calculated the cost of the amount which used for each patient, then we analyzed the 
average for all patient for both procedures separately. Blood tests which carried out before 
and after procedures were taken into account because of differences for both diagnostic 
strategies. These costs are taken into account regardless of who is responsible for paying 
the patient himself or the hospital. Hospitalization costs after the procedure, for the 
observation and recovery period following diagnostic catheterization, were also taken into 
account. Any comorbidities and other patient-independent factors contributions to the 
overhead of the procedure were not included. 
3.13.1.3 Personnel costs 
The salaries of all involved physicians, nurses and medical imaging specialist were also 
determined. Thus, personnel costs were calculated according to collective agreements for 
Palestinian civil service law. The number of medical staff required for each patient was 
determined and multiplied by the average income of this staff. This cost was calculated for 
all patients and the average was obtained for each patient. 
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3.13.2 Induced costs 
Induced costs included the cost of complications associated with the test false-negative 
CAD (Patterson et al., 1984; Patterson et al., 1995; Dorenkamp et al., 2012). In the 
subgroup of patients with false-negative CCTA, a 15% rate of non-fatal myocardial 
infarction over 10 years was assumed (Patterson et al., 1984). Induced cost also associated 
with the complication rates for CCTA (0.004%) and elective ICA (0.05%) were derived 
from the literature (Katayama et al., 1990; Noto et al., 1991; Dewey and Hamm, 2007; 
Hamm et al., 2008; Stacul et al., 2009). 
Costs of complications are difficult to estimate. For this purpose, previously published data 
were combined. It was assumed that the typical complication of both diagnostic tests or of 
untreated CAD would be non-fatal myocardial infarction, requiring hospitalization, 
rehabilitation, chronic medication and repeated follow-up examinations. On average, 
conservative cost estimates for a serious complication amounted to 20000 dollars 
(Patterson et al., 1984; Patterson et al., 1995; Dewey and Hamm, 2007; Stacul et al., 2009; 
Dorenkamp et al., 2012). 
3.13.3 Total costs 
Total costs were calculated as direct costs and indirect cost (as established by the cost 
analysis) times the number of patients tested plus the induced costs (the number of patients 
tested multiplied by the costs of complications produced by test procedures or of CAD 
missed by false-negative test results). By definition, ICA was the gold-standard test in the 
cost-effectiveness analysis with a 100% diagnostic accuracy (sensitivity and specificity of 
ICA=100%) and no non-diagnostic or false results (Montalescot et al., 2014).  
3.14 Cost-effectiveness analysis 
The researcher used the Origin pro 7.0 program to illustrate the cost-effectiveness analysis. 
The cost-effectiveness of each strategy was defined as the cost per correct diagnosis. 
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According to this definition, a lower cost value per correct diagnosis translates into better 
cost-effectiveness. This straightforward approach assumes that the goal of a test is to make 
a diagnosis. In the current study, we estimated the costs of the two different strategies 
relative to their effectiveness intended to correctly diagnose the significant CAD. In 
particular, the cost-effectiveness of the CCTA and ICA was compared when applied to 
patient populations with varying CAD pre-test probabilities. Using a mathematical model, 
we compared the cost-effectiveness for diagnosing the CAD for patient cohorts 
characterized by different pretest likelihood (prevalence) of CAD. 
3.14.1 Model characteristics 
The model is based on Bayes' theorem and consequently assesses cost-effectiveness ratios 
of strategies in hypothetical patient cohorts with different prevalence of disease (Forrester 
et al., 1979). The mathematical model was initially suggested by Paterson and co-workers 
to a comparison of cost-effectiveness for diagnosis of CAD (Patterson et al., 1984; 
Patterson et al., 1995) and was later on applied by others (Stacul et al., 2009; Dorenkamp 
et al., 2012; Boldt et al., 2013; Moschetti et al., 2014; Berrar, 2018).  
3.14.2 Definitions of the effectiveness of tests 
When performing a cost-effectiveness analysis, a wide variety of factors and parameters 
related to the costs and the performances of the tests have to be considered. The model 
must be able to take into account the costs associated with false-positive results (i.e. costs 
of unnecessary diagnostic tests) as well as the costs associated with false negative results 
(i.e. costs of complications because of inappropriate management of the disease). 
The most difficult problem in any assessment of cost-effectiveness is to define the 
effectiveness of healthcare (McNeil et al., 1975; Enthoven, 1978). For our purposes, we 
defined the effectiveness of diagnostic tests in two ways, the first effectiveness criterion 
was the ability of a diagnostic test to accurately identify a patient with CAD. This 
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definition represents a straightforward approach assuming that the single goal of a test is to 
make a diagnosis (Patterson et al., 1984; Patterson et al., 1995; Stacul et al., 2009; 
Dorenkamp et al., 2012). The definition of the second effectiveness criterion was more 
complex and attempted to account for the future health outcome of patients undergoing the 
tests (Patterson et al., 1984; Patterson et al., 1995). It was assumed that a correct diagnosis 
of CAD would enable patients to receive optimal therapy resulting in improved survival 
and well-being. Over the follow-up period, the number of life-years gained (Δ) by CAD 
therapy was adjusted for quality of life, yielding quality-adjusted life years (QALYs). In 
line with previous cost-effectiveness analyses, an accurate diagnosis of CAD was projected 
to increase the number of QALYs by 3 years during a 10-year follow-up (Patterson et al., 
1995). Our model describes the patient flow through the two modalities and the diagnostic 
results and their relationship with the cost and the benefit or adverse health outcome as 
shown in Figure 3.2: 
 
 
 
  
 
 
 
 
Figure 3.2: Schematic of the decision analytic model patients follow up scenarios for cost 
analysis and cost-effectiveness 
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 The cost analysis and cost-effectiveness analysis statistical model illustrate 
possible six scenarios 
1. The first scenario, patients underwent ICA with a positive result (significant CAD ≥ 
50% stenosis). Cost of ICA procedure was calculated and there was benefit health 
outcomes due to diagnosis of CAD and appropriate treatment was done. 
2. The second scenario, patients underwent ICA with a negative result (non-significant 
CAD ˂ 50% stenosis or normal with medical treatment). Cost of ICA was calculated, 
this cost is unjustified and there are adverse health outcomes due to an unnecessary 
procedure.  
3. The third scenario, patients underwent CCTA with a positive result (significant CAD ≥ 
50% stenosis), the patients were a referral to ICA and true positive approved by the 
ICA. Cost of CCTA was calculated and benefit health outcomes were estimated due to 
the correct diagnosis of CCTA.  
4. The fourth scenario, patients underwent CCTA with a positive result (significant CAD 
≥ 50% stenosis), the patients were a referral to ICA and false positive approved by the 
ICA. Cost of CCTA and adverse health outcomes estimated due to an incorrect 
diagnosis of CCTA. 
5. The fifth scenario, patients underwent CCTA with a negative resulted (non-significant 
CAD ˂ 50% stenosis or normal with medical treatment), the patients were a referral to 
ICA, and true negative approved by the ICA. Cost of CCTA was calculated and benefit 
health outcomes were estimated due to the correct diagnosis of CCTA.  
6. The six scenario, patients underwent CCTA with a negative resulted (non-significant 
CAD ˂ 50% stenosis or normal with medical treatment), the patients were a referral to 
ICA and false negative approved by the ICA. Cost of CCTA and adverse health 
outcomes incorrect diagnosis of CCTA. 
45 
 
From previous scenarios, the accuracy of CCTA (sensitivity, specificity, positive and 
negative predictive values) was calculated through the third, fourth, fifth and six scenarios.  
3.14.3 Cost-effectiveness Equations 
Calculations of cost-effectiveness and utility for CCTA and ICA are involved in the 
equations below and Table 3.1 shows different parameters and rates required for cost-
effectiveness equations. 
Direct Costs + Induced Costs 
Effectiveness 
 
 Cost-effectiveness analysis of ICA 
1. Costs = NICA ˟ (DICA+RICA ˟ C) 
whereas       NICA = 1 
2. Effectiveness = NICA ˟ P 
3. ΔQALY = NICA ˟ (ΔQALY) ˟ P − 10 ˟ NICA ˟ MICA- NICA ˟ RICA 
 
 Cost-effectiveness analysis of CCTA 
1. Costs = NCCTA ˟ (DCCTA + RCCTA ˟ C) + NICA ˟ (DICA+RICA ˟ C) + FNCCTA ˟ (RFN ˟ C) 
whereas 
NICA = NCCTA ˟ (1- FPCCTA) ˟ [P ˟ SnCCTA + (1-P) ˟ (1-SpCCTA)] + NCCTA ˟ FPCCTA 
FNCCTA = NCCTA ˟ (1- FPCCTA) ˟ P ˟ (1-SnCCTA) 
2. Effectiveness = NCCTA ˟ (1- FPCCTA) ˟ P ˟ SnCCTA + NCCTA ˟ P ˟ FPCCTA 
3. ΔQALY = (CADDx) ˟ (ΔQALY) - 10 ˟ (NCCTA ˟ MCCTA + NICA ˟ MICA) - 5 ˟ (FNCCTA 
˟ MFNCCTA) - 10 ˟ (0.1) ˟ (NCCTA ˟ RCCTA + NICA ˟ RICA + FNCCTA ˟ RFN) 
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Table 3.1: Parameters and rates required for cost-effectiveness equations  
Parameters used in calculations 
NCCTA Number of patients having CCTA 
DCCTA Direct costs for CCTA  
RCCTA Rate of complications with CCTA 
C 
Average costs of a complication (assumed to be non-fatal myocardial 
infarction) 
NICA Number of patients having ICA 
DICA Direct and indirect costs for ICA 
RICA Rate of complications with ICA 
FNCCTA Rate of patients with false-negative CCTA  
RFN 
Rate of complications per 10-year follow-up period for patients with CAD 
and false-negative tests 
FPCCTA Rate of false positive CCTA  
P Prevalence of CAD in patient cohort 
SnCCTA Sensitivity of CCTA 
SpCCTA Specificity of CCTA 
CADDx Effectiveness 
ΔQALY 
Quality-adjusted life years extended by therapy after making diagnosis of 
CAD (per 10 years of follow-up) 
MCCTA Mortality rate due to CCTA 
MICA Mortality rate due to ICA 
MFNCCTA Mortality per 10 years for patients with CAD but false negative CCTA 
 
3.15 Study constraints 
The following constraints faced the researcher during carrying out of the study:  
 Limited educational resources, particularly professionals in CCTA.  
 Limited availability of the up-to-date journals and international publications.  
 Lack of local researches on cost-effectiveness resources. 
 Cut-off the CCTA and ICA examinations due to break down the equipment at the 
governmental hospitals. 
 Contextual limitation includes the electricity cuts. 
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Chapter 4: Results and discussion 
4.1 Introduction  
This chapter presents the results of the statistical analysis of the data and the interpretation 
of these results in light of other studies. Firstly, it demonstrates the descriptive statistics of 
the study variables. The descriptive analysis represents the demographic characteristics of 
the study participants. Secondly, it assesses the inferential analysis to identify the 
predictors' factors for the significant CAD. Thirdly, it identifies the accuracy of CCTA 
compared with ICA, which consider as a reference. Finally, for the economic evaluation, 
the costs of both diagnostic approaches were identified through a detailed analysis of both 
involved procedures. Additionally, the cost-effectiveness of the two procedures was 
estimated in which both costs and outcomes are examined concurrently.  
4.2 Preliminary descriptive analysis 
Descriptive statistics for the key factors in the study, according to the two diagnostic 
modalities (CCTA and ICA) aims to better understanding of the nature of the data and 
paving the way to the inferential analysis in the next section.  
A total of 381 cases are designated from Al-Shifa hospital. Of these cases, 131 (34.38%) is 
selected as a census survey who have been diagnosed by CCTA. The rest of the cases are 
250 (62.62%) who have been diagnosed by ICA. As well, 58 cases out of 250 have been 
referred from CCTA to ICA to confirm the diagnosis during the study period. 
4.2.1 Demographic characteristics  
Gender distribution in the sample shows that there are 243 (63.8%) male and 138 (36.2%) 
female. Patients are distributed almost consistently according to the diagnostic modalities 
as given in Table 4.1. Furthermore, the Chi-square test of independence reveals that the 
patients' gender has an insignificant incidence of the diagnostic modality, where (Chi-
square test = 0.121 and P-value = 0.728). 
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Table 4.1: Cross tabulation of diagnostic modalities versus gender, (n =381) 
 
Diagnostic 
Modalities 
Gender 
Male 
n (%) 
Female 
n (%) 
CCTA 82 (62.6%) 49 (37.4%) 
ICA 161 (64.4%) 89 (35.6%) 
Total 243 (63.8%) 138 (36.2%) 
 
It is noticeable from these results that the proportion of males far exceeds the proportion of 
females, even if the diagnostic modality varies. Within in-depth interviews, experts 
cardiologist interpret our results as one said:  
“Symptoms in females are often vague and common with other symptoms. From 
our experience, we note that a high proportion of male patients presented with 
CAD compared to female patients. Hence, we prefer to use the initial diagnosis 
(Stress ECG, ECG and ECHO) without exposing the females to the risk of 
radiation which they receive from the CCTA or ICA. Also, male patients have 
excess risk factors than females such as smoking and stress”. 
This interpretation is parallel with a local study conducted by Jamee et al. (2013) for 
identifying the gender difference and characteristics attributed to CAD in Gaza-Palestine 
and revealed that myocardial infarction was the male has two times higher than female in 
admitted patients (53.3% males versus 25.7% females); this difference is statistically 
significant (P-value = 0.004). 
Concerning to age, the mean age of all patients in the sample is 54.31 years with standard 
deviation of 8.26 years. Independent samples t-test shows that there is a significant 
difference between the means of age with respect to the diagnostic modalities at 0.05 level 
of significance (P-value = 0.012) as given in Table 4.2, where the mean age of patients 
diagnosed by CCTA is 55.77 years while the mean age of patients diagnosed by ICA is 
53.55 years.  
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Table 4.2: Independent samples t-test for difference between the means of age with 
respect to the diagnostic modalities. 
Diagnostic 
modalities 
Mean 
(year) 
Standard 
deviation 
Mean 
difference 
T- value P-value 
CCTA 55.77 9.452 
2.223 2.337 0.012* 
ICA 53.55 7.461 
  * Significant at 0.05 level of significance. 
Ageing predisposes to a high incidence and prevalence of CAD in both men and women. 
Knowing the prevalence of CAD in the population helps the physician to estimate pretest 
probability. Our results indicate that the mean age of the study populations is 54.31 years, 
which is close to previous studies. The age is a risk factor that increases the likelihood of 
CAD when associated with other risk factors. In men, the risk for CAD increases starting 
at age 45 and in women, the risk for CAD increases starting at age 55 (Ridker et al., 2007; 
Min et al., 2011; Nakazato et al., 2014). Risk factors associated with CAD in Gaza studied 
by Khwaiter (2009) indicate that distribution of risk factor value of mean age was 57.3 
years. Another local study accompanied by Eljedi and Mushtaha (2015) showed that 78% 
of the CAD group were male and 36% of them aged between 50-59 years old. 
Consequently, it necessary to CAD risk stratification according to age group with respect 
to clinical data to a direction of optimal diagnosis approach.  
4.2.2 History of cardiac medical intervention 
The history of cardiac medical intervention was categorized into three categories, where 32 
(8.4%) of patients are with prior angioplasty (stent or balloon), 63 (16.5%) patients are 
with prior CABG and 286 (75.1%) patients have never had any cardiac medical 
intervention. Furthermore, the Chi-square test of independence reveals that the history of 
cardiac medical intervention has a significant incidence on the diagnostic modality, where 
(Chi-square test = 79.995 and P-value ˂0.001). 
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Results from cross tabulation in Table 4.3 show that there are 88.4% of those diagnosed 
with ICA versus 49.6% of those diagnosed with CCTA has no previous cardiac medical 
intervention. Alternatively, there are 4.8% of those diagnosed with ICA versus 38.9% of 
those diagnosed with CCTA had previously CABG. Furthermore, there are 6.8% of those 
diagnosed with ICA versus 11.5% of those diagnosed with CCTA had previously 
angioplasty (stent or balloon). 
Table 4.3: Cross tabulation of diagnostic modalities versus the history of cardiac 
medical intervention, (n =381) 
Diagnostic 
modalities 
History of cardiac medical intervention 
Angioplasty/Stent 
or Balloon 
n (%) 
Coronary Artery 
Bypass Graft 
n (%) 
Non-cardiac medical 
intervention 
n (%) 
CCTA 15 (11.5%) 51 (38.9%) 65 (49.6%) 
ICA 17 (6.8%) 12 (4.8%) 221 (88.4%) 
Total 32 (8.4%) 63 (16.5%) 286 (75.1%) 
 
The previous cardiac medical intervention of the patient is necessary to be obtained 
because it will be the guide to direct the patient to the optimal procedure. From our results, 
about 11.5% of cases that conducted CCTA had previous angioplasty. This in line with 
previous literature that showed some limitations of CCTA in assessment coronary artery 
stent patency and restenosis (Mark et al., 2010; André et al., 2014). Due to these 
limitations, CCTA is not yet recommended for stents <3.0 mm in diameter. However, the 
recent introduction of new options with CCTA may improve the accuracy of the evaluation 
of in-stent restenosis (Fuchs et al., 2013; Yoo et al., 2018). Surveillance ICA is 
recommended after stent supported PCI due to the unpredictable occurrence of in-stent 
restenosis (Zhao et al. 2011; Moradi et al., 2017).  
Regarding the history of CABG, the current results indicate the high proportion of patients 
undergo CCTA (38.9%) compared to only 4.8% undergo ICA. Given the inherent 
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challenges in performing ICA in patients who have CABG, non-invasive techniques CCTA 
has been great to assess graft patency. Clinically, such an evaluation is often required when 
patients present with symptoms suggestive of ischemia for follow up. Barbero and 
colleagues (2016) conducted a systematic review and meta-analysis of ten studies 
representing 959 patients with prior CABG surgery. The pooled sensitivity and specificity 
of detecting complete graft occlusions was 99% as compared to the standard of ICA. These 
impressive estimates of accuracy persisted across all studies regardless of the age of 
patients or grafts. Certain clinical scenarios may have a compelling role for CCTA over 
ICA. CCTA may be much more recommended in the evaluation of proximal or bypass 
graft aneurysms (Hulten and Blankstein, 2012; Mushtaq et al., 2014; Pesenti-Rossi et al., 
2014). CCTA evaluates patients with unknown previous CABG surgical details to know 
the number, location, and pathways of grafts before planning management by ICA. 
Additionally, CCTA before ICA has the potential to the procedure faster and more 
efficient due to an improved understanding of graft anatomy. Given the economic costs and 
the risk of ICA compared with non-invasive CCTA, it would appear attractive to reserve 
ICA only for patients with an elevated risk of disease in the grafts or native vessels distal 
to the surgical anastomoses (Barbero et al., 2017; Eisenberg et al., 2017). 
Concerning to patients without previous cardiac intervention and underwent the diagnostic 
procedures for the first time, the majority of patients that diagnosed with ICA (88.4%) has 
no previous cardiac intervention (angioplasty or CABG). This result disagrees with the 
clinical guideline in a recent publication. The high sensitivity of CCTA makes it the non-
invasive test of choice in the evaluation of CAD. This has now been ratified in national 
guidelines with NICE that recommending CCTA as the first-line investigation for all 
patients presenting with chest pain due to suspected CAD in elective cases with a low 
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probability of CAD risk (Moss et al., 2017). Within in-depth interviews, experts 
cardiologist interpret our results as one said:  
“We prefer to perform ICA for the patient for several reasons, including the 
inability to regulate and reduce the patient's heart rate to the limit which 
required to conduct CCTA. In addition, there is unreliable in the accuracy and 
effectiveness of local CCTA. Moreover, the availability of ICA is more than 
CCTA and we have cultural difficulties for convincing patients to perform the 
new CCTA procedure”. This view is followed by experts radiologist and medical 
imaging specialist as they said: “The CCTA need high experience from medical 
imaging specialist and radiologist, and, most importantly need complete 
cooperation from the cardiologist to good preparation of patients to perform 
optimal CCTA procedure”.  
4.2.3 Estimated Radiation Dose  
The mean radiation dose given for all patients in the sample is 7.987 millisievert (mSv) 
with a standard deviation of 3.23 mSv. Independent samples t-test shows that there is a 
significant difference between the means estimated radiation dose with respect to the 
diagnostic modalities at 0.05 level of significance (P-value ˂0.001) as given in Table 4.4, 
where the mean radiation dose of patients diagnosed with CCTA is 11.589 mSv while the 
mean radiation dose patients diagnosed with ICA is 6.100 mSv.  
Table 4.4: Independent samples t-test for the difference between the means of 
estimated radiation dose with respect to the diagnostic modalities 
Diagnostic 
modalities 
Mean 
(mSv) 
Standard 
deviation 
Mean 
difference 
T- value P-value 
CCTA 11.589 2.3162 
5.489 24.0373 ˂0.001* 
ICA 6.100 1.662 
   * Significant at 0.05 level of significance 
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Ionizing radiation during ICA or CCTA has serious negative biological effects on humans. 
Any cancer risk due to radiation exposure from a single cardiac imaging test depends on 
age (higher with younger age at exposure) and sex (greater for women) (Einstein et al., 
2007; Hausleiter, 2009; Smith-Bindman, 2009). Consequently, an optimal strategy is 
judgmentally to diagnose significant CAD without unnecessary exposing to radiation 
(Neglia et al., 2015). According to our results, the average estimated radiation dose 
enclosed within the strategy of saving radiation dose. In the report conducted by Coles et 
al. (2006), they revealed that radiation dose and attendant risk associated with CCTA 
versus selective diagnostic ICA in the same patients were 14 mSv and 6 mSv, respectively. 
If no dose-saving strategy is applied, it is estimated that effective doses of CCTA may 
reach up to 30 mSv, thus, there is a potential risk of associated radiation-induced 
malignancy (Xu and Zhang, 2010). Within in-depth interviews, experts medical imaging 
specialist interpret our results as one said: 
“Radiation doses differ from one patient to another depending on the size of the 
patient and the imaged area, but in any case, the modern equipment's have the 
property of reducing radiation doses to diminish the risk of radiation”. Experts 
cardiologist interpret our results as one said: “Radiation doses in ICA highly 
dependent on the experience of the cardiologist who performs the ICA procedure 
regarding the time which needs to access to the origin of coronary arteries and 
the ability of visualization the arteries in different views”. 
4.2.4 Diagnosis Results  
The diagnostic results of the ICA and CCTA have been categorized into three categories 
for all patients who underwent the two procedures as given in Table 4.5. The relative 
frequency of diagnosis results reveals that about one fourth (24.7%) of patients have been 
diagnosed as normal, followed by (28.3%)of patients were diagnosed as non-significant 
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CAD (stenosis < 50%). In contrast, there are 47% of patients were diagnosed as significant 
CAD (stenosis ≥ 50%). 
Furthermore, results from cross tabulation in Table 4.5 show that there are 31.3% of those 
diagnosed through CCTA versus 21.2% of those diagnosed through ICA diagnosed as 
normal without CAD. Additionally, there are 39.7% of those diagnosed through CCTA 
versus 22.4% of those diagnosed through ICA have non-significant CAD (stenosis < 50%). 
On the other hand, there are 29% of those diagnosed through CCTA versus 56.4% of those 
diagnosed through ICA have significant CAD (stenosis ≥ 50%). 
Table 4.5: Cross tabulation of diagnostic modalities versus diagnosis result,(n =381) 
Diagnosis Result 
Diagnostic modalities 
Total CCTA  
n (%) 
ICA  
n (%) 
Normal 41 (31.3%) 53 (21.2%) 94 (24.7%) 
Non-significant CAD 52 (39.7%) 56 (22.4%) 108 (28.3%) 
Significant CAD 38 (29%) 141 (56.4%) 179 (47%) 
Total 131(100%) 250 (100%) 381 (100%) 
 
Our results indicate that two third of patients (71%), who underwent CCTA are diagnosed 
without significant disease (31.3% normal and 39.7% non-significant CAD). This result 
exhibits that no need for interventions for those patients with ICA, and only medical 
treatment was advised. Several related studies coincided with our results, and they 
recommended the use of CCTA for the evaluation of low to intermediate risk patients 
presenting with acute chest pain (Chow and Sheth, 2011; Zeb et al., 2014; Gongora et al., 
2017). CCTA can provide more information than ICA on the type and the burden of 
atherosclerotic plaque in the coronary tree. In addition to these high diagnostic and 
prognostic values, CCTA may play an important role as a gatekeeper to avoid inadequate 
performance of ICA. From a similar study, Shaw et al. (2012) examined the impact of 
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CCTA to avoid unnecessary ICA. They observed that the anatomical assessment of CAD 
by CCTA provides not only accurate diagnostic and prognostic implications, but also the 
additional notable benefit of avoiding the unnecessary ICA. Based on this concept, CCTA 
can safely reduce unnecessary ICA as a gatekeeper. 
Regarding patients underwent ICA, results indicate that 43.6% of patients are diagnosed 
without significant disease (21.2% normal and 22.4% non-significant CAD). Additionally, 
56.4% of patients have significant CAD, and they need intervention (PCI or CABG). Close 
to this result a local observational study conducted by Abed and Jamee (2015) studied the 
characteristics and risk factors attributed to CAD in women attended health services in 
Gaza-Palestine, ICA data showed that 55.2% had significant CAD, and 44.8% had no 
CAD. Obviously, the low diagnostic yield of the ICA was reported by these results, which 
is close to an important study conducted by Patel et al. (2010), that revealed a low 
diagnostic yield for obstructive CAD in 38% of patients undergoing the first-time ICA. So, 
highlight the need for improvement in risk stratification strategies to enhance the yield of 
ICA. Furthermore, it raises the question about clinical signs and pre-test investigations that 
should be considered before ICA. In parallel, Therming et al. (2017) confirm the very low 
diagnostic yield of non-invasive and invasive assessment of CAD in current clinical 
practice, particularly in women and in patients with atypical symptoms. Within in-depth 
interviews, experts cardiologist interpret our results as one said: 
 “Although the high proportion of those who do not have either any CAD or non-
significant CAD, this percentage is declining from previous years, and this 
attributed to enhance the concept of initial clinical diagnosis. Furthermore, the 
training of junior cardiologists to identify groups with a high probability of CAD 
and direct toward to complete investigations for the patient then referred to an 
expert cardiologist to judgment if need ICA or not".  
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4.3 Inferential analysis  
4.3.1 Predictors for significant CAD and efficacy patients selection for ICA 
The final result of ICA for diagnosis eligible patients who had suspected CAD is 
categorized into two categories: first category with significant obstructive CAD which is 
defined as more than 50% angiographic diameter stenosis in one or more of the epicardial 
coronary arteries, and the second category is non-significant obstructive CAD who has 
angiographic diameter stenosis less than 50% (Gauchan et al., 2012; Niccoli et al., 2015). 
Regarding patients in stable clinical conditions, guidelines are recommended for 
straightforward ICA to patients have a high probability of significant CAD, and clinical 
follow-up in those with a low probability of non-significant CAD (Montalescot et al., 
2013). In the current study, out of 250 patients diagnosed by ICA, there are 141 (56.4%) 
patients were considered to have a significant CAD, and 109 (43.6%) of them were 
considered to have non-significant CAD. 
Logistic regression is a predictive model for a categorical dependent variable based on a 
set of independent predictors. This section aims to identify the associated factors and 
independent predictors for significant CAD via logistic regression. A set of 9 independent 
variables are considered to build up the logistic regression, specifically (gender, age, 
obesity, lifestyle, smoking status, family history of heart disease, high cholesterol, high 
blood pressure and diabetes).  
4.3.1.1 Baseline characteristics of the ICA patients 
The descriptive statistics of the independent categorical variables are summarized in Table 
4.6. The chi-square test reveals that there is a significant association between the diagnosis 
result of ICA and the all independent variables at 0.05 level of significance. 
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Table 4.6: Chi-square test of independent categorical variables associated with CAD  
Variable Categories 
Diagnosis Result of ICA 
Chi-
square 
test 
P-value Significant 
(CAD) 
Non-
Significant 
(CAD) 
Total 
Gender 
Male 106 (42.4%) 55 (22.0%) 161 (64.4%) 
16.384 < 0.001* 
Female 35 (14.0%) 54 (21.6%) 89 (35.6%) 
Obesity 
Obese 65 (26.0%) 31 (12.4%) 96 (38.4%) 
8.104 0.004* 
Non-Obese 76 (30.4%) 78 (31.2%) 154 (61.6%) 
Lifestyle 
Sedentary 
lifestyle 114 (45.6%) 57 (22.8%) 171 (68.4%) 
23.195 < 0.001* 
Regular 
exercise 27 (10.8%) 52 (20.8%) 79 (31.6%) 
Smoking 
Status 
Smokers 79 (31.6%) 27 (10.8%) 106 (42.4%) 
24.594 < 0.001* 
Non-
Smokers 62 (24.8%) 82 (32.8%) 144 (57.6%) 
Family 
history of 
heart disease 
Yes 32 (12.8%) 6 (2.4%) 38 (15.2%) 
14.094 < 0.001* 
No 109 (43.6%) 103 (41.2%) 212 (84.8%) 
High 
cholesterol 
Yes 47 (18.8%) 15 (6.0%) 62 (24.8%) 
12.627 < 0.001* 
No 94 (37.6%) 94 (37.6%) 188 (75.2%) 
High blood 
pressure 
Yes 36 (14.4%) 14 (5.6%) 50 (20.0%) 
6.158 0.013* 
No 105 (42.0%) 95 (38.0%) 200 (80.0%) 
Diabetes 
Yes 18 (7.2%) 3 (1.2%) 21 (8.4%) 
8.012 0.005* 
No 123 (49.2%) 106 (42.4%) 229 (91.6%) 
  * Significant at 0.05 level of significance. 
4.3.1.2 Simple Logistic Regression 
We calculated the unadjusted odds ratios for 9 independent variables using the univariate 
logistic regression model to determine the risk factors associated with CAD. 
The results of the simple logistic regression analysis. enabled us to determine which 
characteristics were independently associated with the presence of CAD, while the other 
factors remain constant as illustrated in Table 4.7. 
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Table 4.7:Risk factors associated with CAD from Simple Logistic Regression analysis   
Variable 
β 
Coefficient 
Standard 
error 
Unadjusted Odds Ratio 
(95.0% CI) 
Wald 
statistics 
P-value 
Gender 
Male 1.09 0.27 2.97 (1.74-5.08) 15.90 ˂0.001* 
Female - - 1 [Reference] - - 
Age 0.13 0.02 1.14 (1.09-1.2) 32.61 ˂0.001* 
Obesity 
Obese 0.77 0.27 2.15 (1.26-3.66 ) 7.98 0.005* 
Non-Obese - - 1 [Reference] - - 
Lifestyle 
Sedentary lifestyle 1.35 0.29 3.85 (2.19-6.77 ) 22.02 ˂0.001* 
Regular exercise - - 1 [Reference] - - 
Smoking 
Currently smoking 1.35 0.28 3.87 (2.24-6.69) 23.47 ˂0.001* 
Non-smoking - - 1 [Reference] - - 
Family history of 
heart  disease 
Yes 1.62 0.47 5.04 (2.02-12.55) 12.07 0.001* 
No - - 1 [Reference] - - 
High cholesterol 
Yes 1.14 0.33 3.13 (1.64-5.99) 11.94 0.001* 
No - - 1 [Reference] - - 
High blood pressure 
Yes 0.84 0.35 2.33 (1.18-4.58) 5.98 0.014* 
No - - 1 [Reference] - - 
Diabetes 
Yes 1.64 0.64 5.17 (1.48-18.04) 6.64 0.010* 
No - - 1 [Reference] - - 
* Significant at 0.05 level of significance. 
Among these characteristics, the male has an odds ratio of 2.97, which means that a male 
patient has an approximately 3 times higher risk of CAD than they are for female. Age has 
an odds ratio of 1.14, which indicates that with an increase of 1 year in age, the associated 
risk of CAD will also be increased by 14%. The predicted odds for having a significant 
CAD are 2.15 times higher for patients who are obese than they are for non-obese. 
Regarding lifestyle, the sedentary lifestyle is independent of physical activity associated 
with an increased risk of CAD 3.85 times than they are for a regular exerciser. Current 
smokers were 3.87 times at higher risk of developing CAD than non-smokers.  
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The family history of heart disease has a high odds ratio, the odds of having a significant 
CAD are 5 times more likely to have a significant CAD as patients who without a family 
history of heart disease. The odds of having a significant CAD are more than 3 times 
higher for patients who have high cholesterol than they are for patients who do not have 
high cholesterol. The odds of having a significant CAD are 2.33 times higher for patients 
who have high blood pressure than they are for patients who do not have high blood 
pressure. Interestingly diabetes has the highest odds ratio, the odds of having a significant 
CAD are 5.17 times higher for diabetic patients than non-diabetic patients. 
4.3.1.3 Multiple Logistic Regression  
The final effect model was obtained using forward RL variable selection. Based on the 
results of simple logistic regression analysis, the all independent variables with a P-value 
<0.05 were included in the multiple logistic regression analysis. Table 4.8 presents all the 
independent variables appearing in the final model that remained significantly associated 
with CAD.  
The Omnibus Tests of Model Coefficients for the proposed model gives the value of -2 log 
likelihood is 248.78 with an associated value of Chi-square test equals 93.69 at 7 degrees 
of freedom and P-value <0.001, which reveals the existence of an association between the 
independent variable and significant CAD status. Furthermore, the Cox and Snell R
2
 and 
Nagelkerke R
2
 statistics show that the independent variables explained 31.3% and 41.9% 
of significant CAD variability, respectively. Hosmer and Lemeshow Test for the goodness 
of model fit reveal that significance equals 0.418 (no significant differences between actual 
and predicted values) which indicate well-fitting of our predicting logistic regression 
model. A marked improvement showed correct classification rate in our logistic model for 
76.4% of the cases compared to 56.4% in the null model. 
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Table 4.8: Risk factors associated with CAD from Multiple Logistic Regression 
Variable 
Adjusted β 
Coefficient 
Standard 
error 
Adjusted Odds Ratio 
(95.0% CI) 
Wald 
statistics 
P-value 
Age 0.12 0.03 1.12 (1.06-1.18) 18.65 ˂0.001* 
Obesity 
Obese 0.87 0.33 2.39 (1.26-4.55) 7.09 0.008* 
Non-Obese - - 1 [Reference] - - 
Lifestyle 
Sedentary lifestyle 0.76 0.35 2.14 (1.09-4.22) 4.90 0.027* 
Regular exercise - - 1 [Reference] - - 
Smoking 
Currently smoking 1.06 0.33 2.89 (1.51-5.52) 10.53 0.001* 
Non-smoking - - 1 [Reference] - - 
Family history of 
heart  disease 
Yes 1.13 0.52 3.12 (1.11-8.68) 4.68 0.030* 
No - - 1 [Reference] - - 
High blood pressure 
Yes 1.01 0.42 2.74 (1.22-6.18) 5.90 0.015* 
No - - 1 [Reference] - - 
Diabetes 
Yes 1.47 0.69 4.35 (1.13-16.76) 4.55 0.033* 
No - - 1 [Reference] - - 
 * Significant at 0.05 level of significance. 
Not surprisingly, in multiple logistic regression analysis, we observed that the stronger 
independent predictors for the presence of significant CAD at the ICA were the traditional 
risk factors age, obesity, lifestyle, smoking, the presence of family history of heart disease, 
high blood pressure and diabetes. The strongest association was found for diabetes, the 
odds of having a significant CAD are 4.35 times higher for diabetic patients than non- 
diabetic patients. Family history of heart disease although decreased in odds it still has 
significantly high odds ratio 3.12 times, which expressively odds of contributing towards 
the development of CAD. Regarding smoking, it was assessed only qualitatively through 
patient reports, whereas quantitative characteristics such as exposure time and intensity of 
consumption were not considered. Remarkably, current smokers were 2.89 times at higher 
risk of developing CAD than non-smokers. High blood pressure and obesity are more 
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likely developing CAD with slightly increased in odds 2.74 and 2.39, respectively. 
Concerning lifestyle, regular exercise is associated with significant reductions in the 
incidence of CAD and at lower risk 2.15 times than the sedentary lifestyle.  
Nearby to our results, Khwaiter (2009) identified the risk factors associated with CAD in 
Gaza, he found that CAD patients who are at higher risk of overweight are female patients, 
CAD with high relation with diabetic female patients, CAD patients who are at higher risk 
of CAD are sedentary to light activity patients, and the relation between smoking and CAD 
occurrence risks. 
In accord with our results, a case-control study conducted by Eljedi and Mushtaha (2015) 
to identify the risk factors of CAD in Palestinian patients undergoing ICA, their study 
revealed that the most common risk factors were physical inactivity (OR 3.96, P=0.002), 
hypertension (OR 2.73, P<0.001), diabetes (OR 2.21, P=0.006), smoking (OR 1.96, 
P=0.031), and positive family history (OR 2.12, P=0.012). Furthermore, persons with 
hypertension and diabetes are more vulnerable to CAD and had 2.73 and 2.18 times the 
odds of developing CAD respectively. Positive family history of CAD was strongly 
correlated with developing CAD among the case group. 
Close to these results, Costa et al. (2015) assessed the efficacy of patient selection for ICA 
in suspected CAD. Their results indicate that the odds of having a significant CAD male 
gender 3.95 times higher female, odds of having a significant CAD 1.15 times higher for a 
patient with one more year old, the odds of having a significant CAD are 2.02 times higher 
for patients who have high cholesterol than they are for patients who do not have high 
cholesterol. 
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4.4 Diagnostic accuracy of CCTA compared to ICA 
In the current study, we tested CCTA as a gatekeeper to ICA and the possibility to reduce 
the number of ICAs by reliably identifying CAD and improve patient safety while 
maintaining diagnostic accuracy. The accuracy was conducted on 58 patients who 
diagnosed through CCTA and were referred for ICA within the study period either as part 
of clinical work-up (full investigation) or as part of the accurate diagnosis. Sensitivity, 
Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 
CCTA were calculated. ICA is considered the golden standard diagnostic approach. 
Based on per-patient analysis of 58 patients, results from cross tabulation in Table 4.9 
shows that there are 38 patients with positive CAD (significant CAD ≥50% stenosis) and 
20 patients with negative CAD (non-significant CAD) revealed from CCTA. By 
performing ICA to confirm the diagnosis, only 36 patients were correctly diagnosed by 
CCTA (true positive) and two patients incorrectly diagnosed by CCTA (false positive). 
Regarding non-significant CAD diagnosed with CCTA (20 patients), 19 of them were 
correctly diagnosed (true negative), and only one patient was incorrectly diagnosed (false 
negative). 
Table 4.9: Cross tabulation of diagnostic Results of CCTA versus diagnostic Results 
of ICA, (n =58) 
 
 
Diagnostic Results of ICA 
Total 
Positive Negative 
Diagnostic Results of CCTA 
Positive 36 2 38 
Negative 1 19 20 
Total 37 21 58 
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Calculations of CCTA accuracy are summarized in Table 4.10. The overall sensitivity and 
specificity of CCTA technique was 97.3% (95% CI: 85.84% to 99.93%) and 90.48% (95% 
CI: 69.62% to 98.83%), respectively. The positive predictive value was 94.74% (95% CI: 
82.79% to 98.54%) and negative predictive value was 95% (95% CI: 73.23% to 99.25%) 
of CCTA. 
Table 4.10: Calculations of CCTA accuracy 
 
The current results are close to previous studies, very high sensitivity ranging between 
85% and 99% and negative predictive value (NPV) ranging between 83% and 99% were 
reported in three multicenter (Budoff et al., 2008; Meijboom et al., 2008; Miller et al., 
2008).  Opolski et al. (2015) studied the accuracy of CCTA compare to ICA by per-patient 
analysis. Their study confirms that CCTA has high sensitivity (98%) and negative 
predictive values (94%). Other study conducted by Joshi et al. (2016) revealed that the 
overall sensitivity and specificity of CCTA were 100% (95% CI: 39.76%–100%) and 
91.30% (95% CI: 79.21%–97.58%), respectively. In the same study, the positive predictive 
value was 50% (95% CI: 15.70%–84.30%) and the negative predictive value was 100% 
(95% CI: 91.59%–100%) of CCTA was also fairly high in these patients. In inference, 
recent studies, systematic review and meta-analysis confirm that CCTA is considered as a 
gatekeeper for ICA due to the diagnostic accuracy of CCTA for CAD when compared to 
other diagnostic modalities (Budoff et al., 2017; Chaikriangkrai et al., 2018; Meinel et al., 
2018). 
Sensitivity True positive/(True positive +False negative) 36/(36 +1) 97.3% 
Specificity True negative/(True negative +False positive) 19/(19 +1) 90.48% 
PPV True positive/(True positive +False positive) 36/(36 +2) 94.74% 
NPV True negative/(True negative +False negative) 19/(19+1) 95% 
Accuracy (Total positive +Total negative)/Total 36+19/58 94.83% 
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4.5 Cost analysis 
A cost analysis is an important first step before engaging in cost-effectiveness analysis of 
economic evaluation and to determine the suitability or feasibility of a potential procedure. 
The costs of both diagnostic methods were identified through a detailed analysis of all 
involved procedures. In our cost analysis, the following general considerations were taken 
into account: 
1. Operational hours  
Operational hours for MSCT and cardiac catheterization systems were 7 hours/day, 250 
days/year according to the Ministry of Health regulations based on the Palestinian civil 
service law, which regulating working hours and official holidays. 
2. Equipment lifetime 
Equipment lifetime of MSCT equipment and cardiac catheterization was set at 10 years, 
which determined according to categories annually number utilization cases based on the 
European Society of Radiology (ESR) (ESR, 2014). 
3. Procedure time period  
Independent samples t-test shows that there is a significant difference between the means 
of the procedure time period with respect to the diagnostic modalities (CCTA and ICA) at 
0.05 level of significance (P-value ˂0.001) as given in Table 4.11. The mean procedure 
time of CCTA is 10.24 minutes while the mean procedure time of ICA is 37.00 minutes.  
Table 4.11: Independent samples t-test for difference between the means of the 
procedure time period with respect to the diagnostic modalities 
Diagnostic 
modalities 
Mean 
(minute) 
Standard 
deviation 
Mean 
difference 
T-value P-value 
CCTA 10.24 1.894 
-26.756 -64.373 ˂0.001* 
ICA 37.00 6.029 
  * Significant at 0.05 level of significance. 
65 
 
4. Reporting Time Period 
Independent samples t-test shows that there is a significant difference between the means 
of the reporting time with respect to the diagnostic modalities at 0.05 level of significance 
(P-value ˂0.001) as given in Table 4.12. The mean reporting time of CCTA result is 42.02 
minutes while the mean reporting time of ICA result is 12.32 minutes.  
Table 4.12: Independent samples t-test for difference between the means of the 
reporting time period with respect to the diagnostic modalities 
Diagnostic 
modalities 
Mean 
(minute) 
Standard 
deviation 
Mean 
difference 
T-value P-value 
CCTA 42.02 11.073 
29.703 30.543 ˂0.001* 
ICA 12.32 1.568 
  * Significant at 0.05 level of significance 
5. Cost of contrast medium 
Independent samples t-test shows that there is a significant difference between the means 
of the cost of contrast medium per patient with respect to the diagnostic modalities at 0.05 
level of significance (P-value ˂0.001) as given in Table 4.13. The mean cost of contrast 
medium of CCTA procedure per patient is 17.47 dollars while the mean cost of contrast 
medium of ICA procedure per patient is 11.68 dollars. 
Table 4.13: Independent samples t-test for difference between the means of the cost of 
contrast medium per patient with respect to the diagnostic modalities 
Diagnostic 
modalities 
Mean 
(dollar) 
Standard 
deviation 
Mean 
difference 
T-value P-value 
CCTA 17.47 1.753 
5.786 23.950 ˂0.001* 
ICA 11.68 2.954 
  * Significant at 0.05 level of significance 
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4.5.1 Cost analysis of CCTA procedure 
Direct costs for CCTA are defined as the sum of the equipment costs, personnel costs and 
medical supplies cost of CCTA procedures.  
4.5.1.1 Equipment costs 
 Equipment or unit costs of equipment were the sum of purchasing cost and guaranty 
cost which include service contract and maintenance.  
 Costs of equipment per CCTA procedure were calculated as shown in Table 4.14. 
Table 4.14: Calculation steps of equipment cost per CCTA procedure  
Steps Calculations Result 
Cost per year 
= total cost of MSCT equipment/10 year 
equipment lifetime 
= 1172500 dollars /10 year  
117250 dollars 
Cost per day 
= cost per year/250 working days 
= 117250 dollars /250 days  
469 dollars 
Cost per hour 
=  cost per day/7 working hours 
= 469 dollars/7 hours  
67 dollars 
Cost per minute 
= cost per hour/60 minute 
= 67 dollars/60 
1.12 dollars 
Cost per CCTA 
procedure 
= cost per minute x average CCTA procedure 
time 
= 1.12 x 10.24 minute  
11.43 dollars 
Total equipment cost per CCTA procedure 11.43 dollars 
 
4.5.1.2 Personal salaries cost 
 Personal salaries were determined based on the procedure need highly experienced 
employees with a period of time in the work. Thus there is a salary in accordance with 
the years of experience and their certificates. Thus, the salary of the most experienced 
employee was calculated according to civil service law. 
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 Personnel cost is the total salaries of medical imaging specialists, consultant radiologist 
and nursing. Personal cost was estimated on the basis of the procedure time, which 
spends for each patient also the time of reporting. 
 On specific time requirements for CCTA, medical imaging specialists and nursing 
spend only the time of the procedure (10.24 min), but the radiologist spends time 
procedure and time of reporting (10.24 min+42.02 min). 
 Steps for calculations of salary cost per CCTA procedure as the  following: 
1. Salary cost per year = Salary per month (dollar) x12 month 
2. Salary cost per day = Salary cost per year /250 working days 
3. Salary cost per hour =  Salary cost per day/7 working hours 
4. Salary cost per minute = Salary cost per hour/60 minute 
5. Salary cost per CCTA procedure = Salary cost per minute x average CCTA 
procedure time 
 Costs of personal cost per CCTA procedure were calculated as shown in Table 4.15. 
Table 4.15: Personal cost per CCTA procedure 
Personal 
Salary per 
month  
Cost per 
min 
No. of 
employee 
Time 
Cost per 
procedure 
Medical Imaging 
Specialists 
850 dollars 0.10 1 10.24 0.99 
Consultant Radiologist 2000 dollars 0.23 1 52.26 12.02 
Expert Nurse 800 dollars 0.09 1 10.24 0.94 
Total personal salaries cost per CCTA procedure 13.95 dollars 
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4.5.1.3 Medical supplies and blood tests cost 
 Medical supplies cost is the total cost of materials used during the CCTA procedure, 
cost of contrast medium used to visualize the coronary arteries and cost of preparation.  
 Supplies cost and preparation cost were calculated for each patient. Contrast medium 
was calculated as an average of contrast cost for all patients.  
 Costs of supplies per CCTA procedure were calculated as shown in Table 4.16. 
Table 4.16: Medical supplies cost per CCTA procedure 
Medical supplies Costs of supplies per procedure (dollar) 
Cannula 0.22 
Cotton 0.1 
Alcohol 0.1 
Extension tube 1 
Plaster 0.1 
Normal saline 1.5 
Drugs 1.18 
Blood test  3.8 
Contrast medium  17.46 
Total medical supplies cost per CCTA procedure 25.46 dollars 
 
 
4.5.1.4 Direct cost of CCTA 
Direct cost of CCTA per procedure is equal the sum of total equipment cost per procedure 
11.43 dollars, total personal cost per procedure 13.95 dollars and total medical supplies 
cost per procedure 25.46 dollars. Table 4.17 shows summary for the total direct cost per 
CCTA procedure. 
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Table 4.17: Summary for the total direct cost per CCTA procedure 
Total equipment cost per CCTA procedure  11.43 dollars 
Total personal cost per CCTA procedure  13.95 dollars 
Total medical supplies cost per CCTA procedure  25.46 dollars 
Total direct cost per CCTA procedure 50.84 dollars 
 
 
4.5.2 Cost analysis of ICA procedure 
Direct costs for ICA are defined as the sum of the equipment costs, medical supplies cost, 
recovery period and personnel costs of ICA procedures. 
4.5.2.1 Equipment costs of ICA procedure 
 Unit costs of equipment were the sum of purchasing cost and guaranty cost which 
include service contract and maintenance.  
 Costs of equipment per ICA procedure were calculated as shown in Table 4.18. 
Table 4.18: Calculation steps of equipment cost per ICA procedure  
Steps Calculations Result 
Cost per year 
= total cost of Catheterization  equipment/10 years 
equipment lifetime 
= 1147500 dollars /10 years  
114750 
dollars 
Cost per day 
= cost per year /250 working days 
= 114750 dollars /250 days  
459 dollars 
Cost per hour 
=  cost per day /7 working hours 
= 459 dollars/7 hours  
65.57 
dollars 
Cost per minute 
= cost per hour/60 minutes 
= 67/60 
1.09 
dollars 
Cost per ICA 
procedure 
= cost per minute x average ICA procedure time 
= 1.09 x 37 minute  
40.44 
dollars 
Total equipment cost per ICA procedure 40.44 dollars 
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4.5.2.2 Personal salaries cost of ICA procedure 
 Personnel salaries cost of medical imaging specialists, consultant cardiologist and 
nursing were also determined. Personal cost was estimated on the basis of the 
procedure time which spends for each patient also the time of reporting and recovery. 
 On specific time requirements for ICA, medical imaging specialists and nursing spend 
only the time of the procedure (37 min), and others nursing spends only the time of the 
recovery (11.40 min ), but the cardiologist spends time procedure and time of reporting 
(37 min+12.32 min). The time requirements for ICA is considered direct cost, but the 
recovery time spends not only for one patient, so we calculated by indirect cost as 
attributed to the cost of the procedure. 
 Steps for calculations of salary cost per ICA procedure as the same mentioned in 
CCTA. 
 Costs of direct personal cost per ICA procedure were calculated as shown in Table 
4.19. 
Table 4.19: Total personal direct cost  per ICA procedure 
Personal 
Salary per 
month  
Cost per 
min 
No. of 
employee 
Time 
Cost per 
procedure 
Medical Imaging 
Specialists 
850 dollars 0.10 1 37 3.59 
Consultant 
Cardiologist 
2000 dollars 0.23 2 49.32 22.55 
Expert Nurse 800 dollars 0.09 2 37 6.77 
Total personal salaries direct cost per ICA procedure 32.91 dollars 
 
 
 The indirect cost of the salary of recovery nurse per ICA procedure was calculated as 
the annual salary is divided by the average number of cases conducted per year. Then 
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multiplied by a number of the nurse who service all patients during the recovery 
period. Table 4.20 shows the indirect cost of nurse salary during the recovery period.  
Table 4.20 Indirect cost estimated from recovery per ICA procedure 
Personal 
Salary 
per 
month 
Salary per 
year 
No. of 
annual 
cases 
Nurse 
salary cost 
per 
procedure 
No. of 
nurses 
Cost per 
procedure 
Recovery 
Nurse 
800 9600 1684 5.7 2 11.40 
Indirect cost of the salary of the recovery nurse per ICA procedure 11.40 dollars 
 
Finally, total personal cost per ICA procedure was estimated from the summation of direct 
and indirect cost as shown in Table 4.21. 
Table 4.21: Total of personal cost per ICA procedure 
 
 
4.5.2.3 Medical supplies and blood test cost of ICA procedure 
 Medical procedure supplies cost were included the materials used during the ICA 
procedure, cost of contrast medium which used to visualization the coronary arteries 
and cost of preparation.  
 Supplies cost and preparation cost were calculated for each patient. Contrast medium 
was calculated as an average of contrast cost of all patients. Other supplies which used 
during the recovery period were also calculated. 
 Costs of supplies per CCTA procedure were calculated as shown in Table 4.22. 
Personal cost Cost per procedure 
Direct cost 32.91 dollars 
Indirect cost 11.40 dollars 
Total of personal cost per ICA procedure 44.31 dollars 
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Table 4.22: Total medical supplies cost per ICA procedure 
Medical supplies 
Costs of supplies per 
procedure (dollar) 
Cannula 0.22 
Cotton 0.2 
Alcohol 0.1 
Extension tube 1 
Plaster 0.1 
Normal saline 1.5 
Femoral   sheath F6 11 cm ( Kit ) 15 
Coronary Guide wire  J TIP  0.035 -  150 cm 18 
Jodkins left  JL 4 catheter  Fr 6 22 
Jodkins right JR 4 catheter  Fr 6 22 
Lower lock syringe 12c 2 
Manifold 3 way- right off 5 
Pressure line male – female 100 cm 5 
Puncture needle G 18, 7cm 3 
Gauze  2 
Poledin 10 % 0.3 
Syringe 3ml -10 ml -20 ml 0.21 
Needle G21 0.02 
Intravenous set 0.15 
Blood test 35 
Contrast medium 11.68 
Recovery supplies 5 
Total medical supplies cost per ICA procedure 149.48 dollar 
 
Finally, the total cost of ICA per procedure is equal to the sum of equipment cost per ICA 
procedure (40.44 dollars), total personal cost per examination (44.31 dollars) and total 
medical supplies cost per ICA procedure (149.48 dollars). Table 4.23 shows the total cost 
(direct and indirect) per ICA procedure. 
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Table 4.23: Total cost per ICA procedure 
Total equipment cost per ICA procedure  40.44 dollars 
Total personal cost per ICA procedure 44.31 dollars 
Total medical supplies cost per ICA procedure 149.48 dollars 
Total direct and indirect cost per ICA procedure 234.23 dollars 
 
4.6 Cost comparison CCTA versus ICA 
Summarized cost categories for both diagnostic approaches are displayed in table 4.24. The 
overall direct costs of ICA were found to be about 4.6 times the cost of CCTA, mainly due 
to higher materials and supplies costs (5.9 times), equipment costs (3.5 times), and 
personnel costs (3 times). This ratio is markedly lower than those reported in previous 
studies, which have found that the cost of ICA exceeds that of CCTA up to a factor of nine 
(Dewey and Hamm, 2007; Stacul et al., 2009; Halpern et al., 2010). However, the latter 
studies have, at least partly, applied inconsistent cost-accounting practices, and thus, the 
results might not be directly comparable. However, the main factor that contributes to the 
low-cost ratio between CCTA and ICA is the relatively low direct costs of machines, 
reflecting an increasingly different equipment manufactures specifications costs. In 
contrast, the current results are nearly close to the study conducted by Dorenkamp et al. 
(2012), which revealed that the overall direct costs of ICA were found to be about three 
times the cost of CCTA, mainly due to a partial similarity of MSCT equipment 
specifications. 
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Table 4.24: Cost comparison CCTA versus ICA 
Cost category CCTA (in dollar) ICA (in dollar) 
Equipment 11.43 40.44 
Materials and supplies 13.95 44.31 
Personnel 25.46 149.48 
Total 50.84 234.23 
 
4.6.1 Cost of unnecessary and adverse health outcome of ICA 
The cost to patients and healthcare systems is considerable in parallel to patient safety 
which is a critical policy issue. Many adverse events can be systematically prevented 
through better policy and practice, with the cost of prevention typically much lower than 
the cost of harm. ICA is valuable in patients with high risk of CAD, but, many individuals 
currently undergoing ICA will not benefit from ICA. Therefore, if there are noninvasive 
alternatives to guide decisions about the use of ICA to spare individuals from undergoing 
unnecessary ICA, there is potential to improve health outcomes. 
Based on Figure 3.2 which show the scenario in case of unnecessary to ICA, Table 4.5 
which show the number of patients with non-significant CAD and cost of  ICA procedure 
from Table 4.24, we estimate the cost of unnecessary and adverse health outcome of ICA 
according to ICA cost equation as the following:  
 Total cost of unnecessary and adverse health outcome the selected sample (250 
patients)    
= NICA ˟ (DICA+RICA ˟ C) 
= 109 x (109 + 0.05% x 20000)  
= 26621dollars 
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4.7 Cost per patient tested  
Figure 4.1 shows the cost per patient tested in relation to different prevalence of CAD. 
These results indicate that the cost of both CCTA and ICA are equally at prevalence 57%. 
The cost of CCTA increased as a linear function of CAD prevalence (direct relation 
between false diagnosis and prevalence). In contrast, the cost for ICA did not increase 
significantly (no false diagnosis, both sensitivity and specificity are 100%). Cost increases 
with CAD prevalence for CCTA but not significantly for ICA. CCTA showed lower cost 
than ICA with CAD prevalence <57% but higher costs with CAD prevalence >57%. 
Figure 4.1 Effects of disease prevalence on cost 
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4.8 Impact of CAD prevalence on cost-effectiveness in term cost per effect 
As cost per effect is the inverse of cost-effectiveness, the hyperbolic decrease in cost per 
effect indicates increased cost-effectiveness. Despite the increase in total cost with 
increasing prevalence of CAD especially in CCTA, cost-effectiveness improved with 
different CAD prevalence for both diagnostic tests. Figure 4.2 plots cost per effect (cost 
per patient with CAD diagnosed accurately) versus increasing prevalence of CAD.  
Figure 4.2: Effects of disease prevalence on cost-effectiveness in term cost per effect 
In comparison, CCTA was more cost-effective up to a CAD prevalence of 54%, the cost 
for one patient correctly diagnosed as having CAD was 449.7 dollars with CCTA and 
452.3 dollars with ICA. Given the 64% CAD prevalence of the investigated patient cohort 
in the current study, the cost for one patient correctly diagnosed as having CAD was 425.2 
dollars with CCTA and 381.6 dollars with ICA. At a CAD prevalence of 55%, CCTA and 
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ICA were equally effective with costs of 448 dollars. With higher disease prevalence 
(>55%), ICA became more cost-effective. In particular, the data demonstrate that CCTA is 
more cost-effective in patients with a prevalence up to 54%, with a cost per correct 
diagnosis of CAD ranging from 1139.1dollars (10% prevalence) to 449.7 dollars (54% 
prevalence). By contrast, ICA shows better cost-effectiveness for a prevalence of 56%–
100%, with a cost per correct diagnosis of CAD between 436.13 dollars (56% prevalence) 
and 244.23 dollars (100% prevalence). Cost and prevalence are inversely proportional in 
both CCTA and ICA as shown in Table 4.25. 
Table 4.25: Cost-effectiveness of CCTA and ICA at different levels of CAD 
prevalence in term cost per effect 
Cost-effectiveness (dollar) Cost/CAD Dx 
Prevalence CCTA ICA 
10% 1139.1 2442.3 
20% 716 1221.2 
30% 575 814.1 
40% 504.5 610.6 
50% 462 488.5 
54% 449.7 452.3 
55% 448 448 
56% 443.9 436.13 
60% 434 407.1 
70% 413.9 384.9 
80% 398.8 305.3 
90% 387 271.4 
100% 377.6 244.23 
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4.9 Impact of CAD prevalence on cost-effectiveness in terms of ΔQALY  
Figure 4.3 plots cost per cost-effectiveness in terms of ΔQALY versus increasing 
prevalence of CAD. The decrease in cost per ΔQALY indicates increased cost-
effectiveness. Regardless of the increase in cost with increasing prevalence of CAD 
especially in CCTA, ΔQALY improved with different CAD prevalence for both diagnostic 
tests. At a CAD prevalence of 55%, CCTA and ICA were equally effective in term 
ΔQALY with costs of 150 dollars. CCTA was more cost-effective in term ΔQALY up to a 
CAD prevalence of 54% ranging from 399.21 dollars (10% prevalence) to 128.06 dollars 
(54% prevalence). By contrast, ICA shows better cost-effectiveness for a prevalence of 
56%–100%, with a cost per in term ΔQALY of CAD between 146.55 dollars (56% 
prevalence) and 81.79 dollars (100% prevalence) as shown in Table 4.26.   
Figure 4.3 Effects of disease prevalence on cost-effectiveness in terms of ΔQALY 
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Table 4.26: Cost-effectiveness of CCTA and ICA at different levels of CAD 
prevalence in terms of ΔQALY 
Cost-effectiveness (dollar) QALYs 
Prevalence CCTA ICA 
10% 399.21 852.46 
20% 245.84 416.42 
30% 196.42 275.5 
40% 171.89 205.84 
50% 157.24 164.3 
54% 128.06 152.03 
55% 150 150 
56% 150.92 146.55 
60% 147.49 136.71 
70% 140.55 117.05 
80% 135.34 102.34 
90% 131.30 90.91 
100% 128.06 81.79 
From a cost-effective point of view, our results indicate that the range of patients eligible 
for CCTA is smaller than previously believed and that ICA becomes the more cost-
effective diagnostic approach at a disease prevalence > 55%. These findings are supported 
by guidelines on the assessment and diagnosis of recent onset chest pain issued by the 
NICE. According to NICE guidelines, CCTA is recommended if a patient has a 10-29% 
prevalence for CAD. The guideline further recommends ICA as the most cost-effective 
first test if the prevalence of CAD is >61% (Skinner et al., 2010). Close to our results, a 
study conducted by Dorenkamp et al. (2012) that revealed above a threshold value of 
disease prevalence of 55%, proceeding directly to ICA was more cost-effective than 
CCTA. In contrast to our results, two previous studies applied different cost-accounting 
practices and largely overestimated the costs of ICA or the rate of severe complications 
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associated with ICA. One of these previous studies demonstrated that CCTA is cost-
effective in patients up to 60-70% prevalence for CAD, whereas ICA is the most cost-
effective preferred approach in patients with a higher prevalence (Dewey and Hamm, 
2007). The second study found CCTA to be more cost-effective than ICA even up to a 
prevalence for CAD of 86% (Stacul et al., 2009).  
4.10 Sensitivity analysis of variables influencing cost-effectiveness 
A sensitivity analysis was performed to evaluate whether some key parameters used in the 
mathematical model are robust within a certain range of uncertainty. Thus, cost-
effectiveness calculations were repeated after:  
1. Increasing and decreasing the rates of complications associated with invasive coronary 
angiography (RICA= 0.1% and 0.01%) (Patterson et al., 1984; Patterson et al., 1995; 
Dorenkamp et al., 2012; Boldt et al., 2013). 
2. Taking into account higher and lower costs of complications (C=25000 dollars and 
10000 dollars) (Patterson et al., 1984; Patterson et al., 1995; Dorenkamp et al., 2012; 
Boldt et al., 2013). 
3. Increasing and decreasing CCTA sensitivity (SnCCTA= 85.84 and 99.93) and specificity 
(SpCCTA= 69.62 and 98.83) concerning to our accuracy calculations. 
We systematically changed the numerical values of previous key parameters in the 
equations. Increasing (0.1%) or decreasing (0.01%) the rates of complications associated 
with ICA changed the cost-effectiveness threshold of CCTA marginally (56% and 53% 
CAD prevalence, respectively). With higher (25000 dollars) costs of complications, the 
cost-effectiveness of CCTA decreased marginally up to a CAD prevalence of 51%, but 
with lower (10000 dollars) costs of complications, the cost-effectiveness of CCTA was 
significantly increased up to a CAD prevalence of 62%. The most substantial changes 
occurred at maximally decreased and increased diagnostic accuracies. However, CCTA 
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remained prominent significantly more cost-effective than ICA up to a disease prevalence 
of 77%, in contrast with maximum decreased diagnostic accuracies, the cost-effectiveness 
decreased dramatically to 14%.  
Finally, one of the key requirements of cost-effectiveness analysis is the identification cost 
per effect, which means is decrease cost with high benefit indicates increase cost-
effectiveness. Likewise, as the prevalence of CAD increased, there were decreased costs 
per utility unit in terms of QALYs gained indicating increased cost-utility at higher disease 
prevalence. Thus, despite the fact that total costs increased with increasing prevalence of 
CAD, cost per effect and cost per utility improved. The hyperbolic relationship between 
CAD prevalence and cost per effect or cost per utility implicates very high costs per effect 
or utility unit at low disease prevalence. At a low prevalence of CAD, the rank order of 
cost per utility unit was principally the same as that of cost per effect in CCTA. Again, the 
rank order of tests changed at high disease prevalence and performing ICA as the first and 
only test was the most cost-effective diagnostic approach at high disease prevalence. 
Our analysis shows cost-effectiveness CCTA for diagnosing CAD in patients suspected as 
having mild to intermediate CAD. Thus, the most important step for physicians in selecting 
the appropriate diagnostic approach (CCTA versus ICA) is based on a clinical estimation 
of disease prevalence. The score by Morise et al. (1997) provides an easy, memorable and 
accurate method for categorizing and subcategorizing patients with suspected CAD into 
probability groups upon which decisions concerning diagnostic testing could be based. 
Although ICA remains the gold standard for diagnosing CAD, carefully performed CCTA 
may be an economically efficient alternative to ICA, especially in ruling out CAD in 
patients with an intermediate pretest likelihood. 
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Chapter 5: Conclusion and Recommendations 
5.1 Conclusion 
The health economics of care pathways in the Gaza Strip have become under greater 
scrutiny due to increasing financial pressures on healthcare providers due to a scarcity of 
medical supplies. Cost-effective care pathways are fundamental to provide sustainable 
healthcare programs. Due to the overestimation of CAD using traditional risk tables, non-
invasive testing has been utilized to improve risk stratification and initiate appropriate 
management to reduce the dependence on invasive investigations. In line with recent 
technological developments, CCTA is a modality that offers a detailed anatomical 
assessment of CAD comparable to ICA. The present study was carried out for project 
clinical outcomes, health care costs, and cost-effectiveness of CCTA, as compared with 
ICA, in the evaluation of patients with suspected CAD. Two group sample considered of 
381 cases are elected from Al-Shifa hospital. Of these cases, 131 (34.38%) is selected as a 
census survey who have been diagnosed by CCTA. The rest of the cases are 250 (62.62%) 
selected who have been diagnosed by ICA. As well, 58 cases out of 250 have been referred 
from CCTA to ICA to confirm the diagnosis. Gender distribution shows that there are 243 
(63.8%) male and 138 (36.2%) female with mean age of all patients in the sample is 54.31 
years. The majority of patients that diagnosed with ICA (88.4%) has no previous cardiac 
intervention (angioplasty or CABG). This result disagrees with the clinical guideline 
ratified CCTA as the first-line investigation for all patients with suspected CAD. 
Regarding the estimated radiation dose, patients diagnosed with CCTA is receive 
approximately twice radiation with ICA, however, these doses enclosed within the strategy 
of saving radiation doses.  
The low diagnostic yield of elective ICA was prominent in our study, about 56.4% of 
patients underwent ICA were considered to have a significant CAD, about 43.6% were 
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considered to have non-significant CAD. Consequently, baseline characteristics, such as 
gender, age, obesity, lifestyle, smoking status, family history of heart disease, high 
cholesterol, high blood pressure and diabetes were collected to predict the efficacy of 
patient selection for ICA in suspected CAD. The simple logistic regression analysis 
showed all variables significantly associated (P < 0.05) with the presence of significant 
CAD (stenosis ≥ 50 ). Multiple logistic regression showed that the stronger independent 
predictors for the presence of significant CAD at the ICA were the traditional risk factors 
age, obesity, lifestyle, smoking, the presence of family history of heart disease, high blood 
pressure and diabetes. The diagnostic yield and accuracy of CCTA in patients referred for 
ICA based on clinical concern for CAD and clinical criteria determined by cardiologist 
according to patients complain. We enrolled 58 patients underwent CCTA prior to ICA, 
then we analyzed the prevalence of potentially significant CAD ( ≥ 50% stenosis) on 
CCTA and calculated the diagnostic accuracy of ≥ 50% stenosis on CCTA for the 
detection of clinically significant CAD on ICA. ICA is the gold standard with a 100% 
sensitivity and 100% specificity. Compared to ICA, CCTA's sensitivity, specificity, NPV, 
PPV for diagnosis CAD were, 97.3%, 90.48%, 95% and 94.83%, respectively. These 
results confirm that CCTA appears to be an effective noninvasive alternative to exclude 
CAD. 
Cost of CCTA and ICA per patient tested in relation to different prevalence of CAD shows 
that CCTA increased as a linear function of CAD prevalence. In dissimilarity, the cost for 
ICA did not increase significantly. Cost increases with CAD prevalence for CCTA but not 
significantly for ICA. In parallel, CCTA showed lower cost than ICA with CAD 
prevalence < 57%, but higher costs with CAD prevalence > 57%. Although the increase in 
total cost with increasing prevalence of CAD, cost-effectiveness improved with different 
CAD prevalence for both diagnostic tests. In comparison, CCTA was more cost-effective 
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up to a CAD prevalence of 54%, cost for one patient correctly diagnosed as having CAD 
was 449.7 dollars with CCTA and 452.3 dollars with ICA. Given the 63.8% CAD 
prevalence of the investigated patient cohort, cost for one patient correctly diagnosed as 
having CAD was 425.5 dollars with CCTA and 382.9 dollars with ICA. At a CAD 
prevalence of 55%, CCTA and ICA were equally effective with costs of 448 dollars. With 
higher disease prevalence (>55%), ICA became more cost-effective. 
The decrease in cost per ΔQALY indicates increased cost-effectiveness. Regardless of the 
increase in cost with increasing prevalence of CAD, ΔQALY improved with different 
CAD prevalence for both diagnostic tests. At a CAD prevalence of 55%, CCTA and ICA 
were equally effective in term ΔQALY with costs of 150 dollars. 
CCTA was more cost-effective in term ΔQALY up to a CAD prevalence of 54% ranging 
from 399.21 dollars (10% prevalence) to 128.06 dollars (54% prevalence). By contrast, 
ICA shows better cost-effectiveness for prevalence of 56%–100%, with a cost per in term 
ΔQALY of CAD between 146.55 dollars (56% prevalence) and 81.79 dollars (100% 
prevalence) 
Finally, data call for a more rational approach to avoid unnecessary testing and 
appropriate utilization of noninvasive diagnostic testing is important to ensure that patients 
with CAD are referred to ICA for diagnosis and that patients who do not have CAD can 
avoid unnecessary invasive testing. Although ICA has been the gold standard for 
evaluating CAD, it should not be routinely performed as an initial test to assess CAD in 
patients with suspected CAD by the recent guidelines, due to cost, invasiveness, and 
measurable risk (Montalescot et al., 2014). CCTA is a rapidly growing, non-invasive 
imaging modality that developed quickly over the last decade, and its role for evaluation of 
CAD becomes of great promise with high diagnostic accuracy (Meijboom et al., 2008; 
Miller et al., 2008).  
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5.2 Recommendations 
Based on the study analysis, findings and conclusions, the researcher propose the following 
recommendations: 
1. Invasive coronary angiography should be considered for patients with CAD whose 
clinical characteristics and results of noninvasive testing indicate a high likelihood of 
severe stenosis and when the benefits are deemed to exceed the risk. 
2. Patients with suspected CAD should receive a thorough history and physical 
examination to assess the probability of CAD prior to additional testing. 
3. Coronary computed tomography angiography might be reasonable for patients with a 
low to intermediate pretest probability of CAD who have at least moderate physical 
functioning or no disabling comorbidity. 
4. Patients with CAD diagnosed by CCTA should be carefully followed to monitor the 
progression of disease, complications and adherence. 
5. Choices regarding diagnostic options should be made through a clear policy of shared 
decision-making with explaining information about risks, benefits, and costs to the 
patient. 
6. Coronary computed tomography angiography can be useful as a first-line test for risk 
assessment in patients with suspected CAD to an adequate workload. 
7. Invasive coronary angiography is not recommended to assess risk in asymptomatic 
patients with no evidence of ischemia on CCTA. 
8. The low cost and high sensitivity of CCTA make it the non-invasive test of choice in 
the evaluation of non-significant CAD. 
9. The supervising cardiologist should have advanced knowledge and expertise in CCTA. 
Certification of advanced expertise in CCTA is desirable. 
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10. Avoidance of unnecessary ICA may result in cost savings, even if positive results 
require confirmation by ICA. 
11. In higher risk population a strategy of sending all patients directly to ICA is likely to be 
cost-effective. 
12. The performance and interpretation of CCTA require special training is recommended 
to maintain competence in the procedure. 
13. The rapid technological advances of CCTA have raised promise that this imaging 
modality may fulfill the role of a gold-standard non-invasive investigation of the CAD.  
 
5.2.1 Recommendation for further researches 
1. Enhancement researches to focus on investigating the merit of integrating CCTA into 
patient management and to determine its effect on treatment and clinical outcomes. 
2. Future study protocols should delineate, a priori, possible adverse events and 
consequences (including those related to psychological aspects of testing and radiation 
exposure) and report their occurrence per the protocol. 
3. Forthcoming studies should incorporate standardized, validated measures for patient-
reported outcomes and document the impact of testing, including downstream testing, 
on patient psychological status (particularly with false positive results), health status 
and resource use. 
4. Additional sufficiently powered studies examining the impact of testing on hard 
clinical outcomes (death, myocardial infarction) at longer-term follow up (>12 months) 
are needed. 
5. Studies (randomize control trials, pragmatic trials or methodologically rigorous 
comparative cohort studies) that compare functional tests using more state of the art 
technology and methods with each other and with anatomic tests are needed.  
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Annex 2: Map of Gaza Strip  
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Annex 3: Sample size calculation 
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Annex 4 Questionnaire for Patient undergo CCTA Procedure 
Serial 
number 
 
ID 
number 
 Date:        /        /    2018 
Hospital:   Al-Shifa  Hospital 
A. Personal Information                                  
A1 Gender  Male  Female 
A2 
Age  ------------  
Years 
A3 
Weight  ------------  
kg 
A4 Height  ------------  cm 
B. Personal Habits 
B1 Lifestyle  
B1.1 Sedentary lifestyle 
 
 
B1.2 
Regular exerciser (30mins more than 5 
days/week) 
 
B1.3 Hard and stress work  
B2 
Smokinghabit 
 
B2.1 Currently smoking    
B2.2 Non smoker  
B2.3 Ex-smoker < 12 months  
B2.4 Ex-smoker >12 months  
C. Medical History   
C1 
Family history of heart  
disease 
 C2 Heart attack  
C3 
Rapid or irregular 
heartbeats 
 C4 Chest  pain or discomfort  
C5 High cholesterol  C6 High blood pressure  
C7 Asthmaor lung disease  C8 Shortness of breath  
C9 History of allergies  C10 Diabetes  
C11 Impaired kidney function  C12 Others……………………………… 
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D. History of  Cardiac Medical Intervention 
D1 
Angioplasty/Stent or 
Balloon 
 D2 Heart Valve Replacement  
D3 
Coronary artery bypass 
Graft  
 D4 Thoracic Vessels Surgery  
D5 Pacemaker  D6 Non cardiac intervention  
E. Previous Cardiac Examination 
E1 
Resting 
Electrocardiography 
 E2 Exercise Stress Test  
E3 
Cardiac 
Echocardiography 
 E4 Cardiac Catheterization  
E5 Prior Calcium Score CT  E6 Coronary artery CT  
E7 Others………………………………… 
F. Pre-Procedure Preparation 
F1 Pulse _ _ _ _beats per minute 
F2 Blood Pressure _ _ _ _mm Hg 
F3 Kidney Function  Urea_ _ _ _mg/dL Creatinine_ _ _ _mg/dL 
F4 Hepatitis Test  
Hepatitis C 
(HCV)  
 Hepatitis B (HBV) 
F5 Coagulation Test PT_ _ _ _ PTT_ _ _ _ INR_ _ _ _  
F6 Beta Blockers Drugs  Yes  No 
F7 Sublingual Nitroglycerin  Yes  No 
G. Appointment Period 
G1 
Emergency 
Appointment 
 G2 Elective  Appointment  
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G3 
Appointment time 
period 
G3.1 Within 24 hours  
G3.2 More than 24 hours to 72 hours  
G3.3 More than 72 hours  to One weak  
G3.4 More than One weak to two weak  
G3.5 More than two weak  
H. Items during CCTA procedure 
H1 Estimated Radiation Dose                       _ _ _ _ mSv 
H2 Contrast Volume                                       _ _ _ _mL 
H3 Procedure time period                            _ _ _ _ minute 
H4 Supplies Used 
H4.1 Cannula  
H4.2 Cotton  
H4.3 Alcohol  
H4.4 Extension tube  
H4.5 Plaster  
H4.6 Normal saline  
H5 Staff of Procedure 
H5.1 Medical Imaging Specialists  
H5.2 Radiologist  
H5.3 Nurse  
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I. Potential Complications of CCTA 
I1 Allergic reaction  I2 Shock  
I3 Death  I4 Others…………………………………… 
J. Diagnosis of CCTA 
J1 Normal  J2 Inconclusive result  
J3 Congenital anomaly  J4 Extra-Cardiac Pathology  
J5 Coronary 
J5.1 Plaque without stenosis  
J5.2 Mild Stenosis <50%  
J5.3 Moderate Stenosis  50%-70%  
J5.4 High stenosis >70%  
J6 Grafts 
J6.1 Occlusion  
J6.2 Significant stenosis  
J7 Stent 
J7.1 Stent Restenosis  
J7.2 Blooming and motion artifacts  
K. Reporting Period 
K1
  
Reporting  time period                      _ _ _ _ minute 
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Annex 5: Questionnaire for Patient undergo ICA Procedure 
Serial 
number 
 
ID 
number 
 Date:        /        /    2018 
Hospital:   AL Shifa  Hospital 
A. Personal Information                                  
A1 Gender  Male  Female 
A2 
Age  ------------  
Years 
A3 
Weight  ------------  
kg 
A4 
Height  ------------  
cm 
B. Personal Habits 
B1 Lifestyle  
B1.1 Sedentary lifestyle 
 
 
B1.2 
Regular exerciser (30mins more than 5 
days/week) 
 
B1.3 Hard and stress work  
B2 
Smokinghabit 
 
B2.1 Currently smoking    
B2.2 Non smoker  
B2.3 Ex-smoker < 12 months  
B2.4 Ex-smoker >12 months  
C. Medical History   
C1 
Family history of heart  
disease 
 C2 Heart attack  
C3 
Rapid or irregular 
heartbeats 
 C4 
Chest  pain or 
discomfort 
 
C5 High cholesterol  C6 High blood pressure  
C7 Asthmaor lung disease  C8 Shortness of breath  
C9 History of allergies  C10 Diabetes  
C11 Impaired kidney function  C12 
Others…………………………
…… 
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D. History of  Cardiac Medical Intervention 
D1 
Angioplasty/Stent or 
Balloon 
 D2 
Heart Valve 
Replacement 
 
D3 
Coronary artery bypass 
Graft  
 D4 
Thoracic Vessels 
Surgery 
 
D5 Pacemaker  D6 
Non cardiac 
intervention 
 
E. Previous Cardiac Examination 
E1 
Resting 
Electrocardiography 
 E2 Exercise Stress Test  
E3 
Cardiac 
Echocardiography 
 E4 Cardiac Catheterization  
E5 Prior Calcium Score CT  E6 Coronary artery CT  
E7 Others………………………………… 
F. Pre-Procedure Preparation 
F1 Pulse _ _ _ _beats per minute 
F2 Blood Pressure _ _ _ _mm Hg 
F3 Kidney Function  Urea_ _ _ _mg/dL 
Creatinine_ _ _ 
_mg/dL 
F4 Hepatitis Test  
Hepatitis C 
(HCV)  
 
Hepatitis B 
(HBV) 
F5 Coagulation Test PT_ _ _ _ PTT_ _ _ _ INR_ _ _ _  
F6 
Complete Blood Count 
(CBC) 
 Yes  No 
F7 Chest X-Ray (CXR)  Yes  No 
G. AppointmentPeriod 
G1 
Emergency 
Appointment 
 G2 Elective  Appointment  
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G3 
Appointment time 
period 
G3.1 Within 24 hours  
G3.2 More than 24 hours to 72 hours  
G3.3 More than 72 hours  to One weak  
G3.4 More than One weak to two weak  
G3.5 More than two weak  
H. Items during ICA procedure 
H1 Site of Incision  Femoral  Radial 
H2 Estimated Radiation Dose                           _ _ _ _ mSv 
H3 Contrast Volume                                           _ _ _ _mL 
H4 Procedure time period                                 _ _ _ _ minute 
H5 Supplies Used 
H5.1 Cannula  
H5.2 Cotton  
H5.3 Alcohol  
H5.4 Extension tube  
H5.5 Plaster  
H5.6 Normal saline  
H5.7 Femoral   sheath F6 11 cm ( Kit )  
H5.8 
Coronary Guide  wire  J TIP  0.035 -  150 
cm 
 
H5.9 Jodkins left  JL 4 catheter  Fr 6  
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H5.10 Jodkins right JR 4 catheter  Fr 6  
H5.11 lower lock syringe 12c  
H5.12 Manifold 3 way- right off  
H5.13 Pressure line male – female 100 cm  
H5.14 Puncture needle G 18, 7cm  
H5.15 Gauze   
H5.16 Poledin 10 %  
H5.17 Syringe 3ml -10 ml -20 ml  
H5.18 Needle G21  
H5.19 Heparin 2 ml  
H5.20 IV sit  
H6 
Staff of 
Procedure 
H6.1 Medical Imaging Specialists 
No.1  
No.2  
H6.2 Cardiologist 
No.1  
No.2  
No.3  
H6.3 Nurse 
No.1  
No.2  
No.3  
No.4  
No.5  
I. Potential Complications of ICA 
I1 
Trauma of the 
arteries, veins and 
nerves 
 I2 Bleeding  
I3 Infection  I4 Allergic reaction  
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I5 Thrombosis  I6 Embolism  
I7 Myocardial infarction  I8 Shock  
I9 Cerebral insult  I10 Emergency operation  
I11 
Cardiopulmonary 
resuscitation 
 I1 Coronary dissection  
I13 Death  I4 
Others………………………………
…… 
J. Diagnosis Results of ICA 
J1 Normal  J2 Inconclusive result  
J3 Congenital anomaly  J4 Ectasia  
J5 
Coronary  J5.1 Plaque without stenosis  
J5.2 Mild Stenosis <50%  
J5.3 Moderate Stenosis  50%-70%  
J5.4 High stenosis >70%  
J6 Grafts 
J6.1 Occlusion  
J6.2 Significant stenosis  
J7 Stent J7.1 Stent Restenosis  
K. Reporting Period 
K1 Reporting  time period                       _ _ _ _ minute 
L. Post ICA Procedure 
L1 Recovery  time period                                   _ _ _ _ hours 
L2 
Recovery Supplies and 
Examination 
Normal saline  
IV sit  
Gauze   
Plaster  
Drugs  
Resting  Electrocardiography  
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Annex 6: Semi-structured in-depth interviews questions 
 For Cardiologists 
1. Is there a standard protocol or clear policy to refer suspected CAD patients to diagnosis 
approach correlated with up to date the international guidelines? 
2. Is the patient gender has an effect on selecting diagnostic modality (CCTA or ICA)? 
3. What do you explain that the majority of patients are male and that the proportion of 
females in both diagnostic modality is limited? 
4. Is the previous cardiac medical intervention of the patient is affected in direct the 
patient to the diagnostic modality? 
5. How satisfied are you with the coronary CT diagnoses performed at our hospital? 
6. What the causes which influence on the radiation dose which received during the ICA? 
7. Which explains that a high proportion of patients who underwent ICA with 
unnecessary for ICA? 
 For Radiologist and medical imaging specialist 
1. What the challenges to perform the optimal CCTA procedure? 
2. There is an application to radiation safety protocol? 
3. What the reasons which influence the radiation dose which received during the CCTA? 
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Annex 7: Approval from Helsinki committee –Gaza governorate 
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Annex 8: An agreement letter from MoH Hospitals General Administration 
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Annex 9: List of experts (interviewees) 
Name Affiliation 
Radiologists 
Dr. Mohammad Mattar Al-Shifa hospital- MoH 
Dr. Saadi Jaber Gaza European hospital- MoH 
Dr. Marwan Mattar Gaza European hospital- MoH 
Cardiologists 
Dr. Mohammed Habeeb Al Shifa hospital- MoH 
Dr. Mohammed Abu Hasiera Al Shifa hospital- MoH 
Medical Imaging Specialist 
Mr. Moussa Abo zour Al Shifa hospital- MoH 
Mr. Moussa Al Nahal Gaza European hospital- MoH 
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Annex 10: List of experts (arbitrators) 
No. Name Affiliation 
1.  
Dr. Yahia Abed Al- Quds University 
2.  
Dr. Ahmed Najim Al Azhar University 
3.  
Dr. Samy Alagha Al Azhar University 
4.  
Dr. Mazen Abo Qamar Al Azhar University 
5.  
Dr. Ihab Naser Al Azhar University 
6.  
Dr. Mohammed Matter MoH 
7.  
Dr. Mohammed Habeeb MoH 
8.  
Dr. Saadi Jaber MoH 
9.  
Dr. Mohammed Abu Hasiera MoH 
10.  
Mr. Ibrahiem Abass MoH 
11.  
Mr. Moussa Abo zour MoH 
12.  
Mr. Maher Soliman MoH 
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 cibarA ni tcartsbA
رايين التاجيت بواسطت الأشعت المقطعيت  مقابل القسطرة القلبيت التشخيصيت في "تصوير الش
 مستشفياث غزة الحكوميت: تحليل فعاليت التكلفت"
 إعذاد: حسام حسن حسين منصور
 ياسر صالح العجرمي /إشراف: الذكتور
 ملخص الذراست
 مقذمت
عثة سئ١غٟ ٌٍٛفاج ٚاٌزٞ  الأِشاع اٌمٍث١ح ذّصً ػةء ٍِؽٛظ فٟ فٍغط١ٓ ، ٚاٌزٞ ٠ؼرثش أٚي
تذسظاخ  )DAC(اٌشػا٠ح اٌظؽ١ح. ذٛظذ ػذج طشق ٌٍرشخ١ض الإشؼاػٟ ٌّشع اٌشش٠اْ اٌراظٟ ِٛاصٔاخ واً٘ ٠ش٘ك
، ٕ٘ان اذعاٖ فٟ ٚصاسج اٌظؽح ٔؽٛ اٌؽاظح إٌٝ لاػذج أدٌح واف١ح ٌرثش٠ش ذىٍفح  فٟ لطاع غضج .ِرفاٚذح ِٓ اٌذلح ٚاٌرىٍفح
ش ِؼٍِٛاخ واف١ح ٌفؼاٌ١ح اٌرىٍفح ِٓ أظً ِغاػذج الأطثاء ٚطٕاع اٌمشاس فٟ اخر١اس عؼ١ا ٌرٛف١ أٞ إظشاء ٚرٌه
 .اعرشاذ١ع١ح اٌرشخ١ض الأوصش فاػٍ١ح
 الهذف من الذراست
 ِماسٔح ِغ ATCCذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح ٘ذفد ٘زٖ اٌذساعح ٌرؽذ٠ذ فؼاٌ١ح اٌرىٍفح ِٓ
 فٟ اٌّشضٝ اٌز٠ٓ ٠شرثٗ ترؼشضُٙ ٌّشع اٌشش٠اْ اٌراظٟ. ACIاٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح 
 منهجيت الذراست
اٌذساعح ػثاسج ػٓ دساعح ذؽٍ١ٍ١ح ٌث١أاخ ذُ ظّؼٙا (وّ١ح ٚ ٔٛػ١ح)، اٌىّ١ح تاعرخذاَ اعرثأح ٌعّغ اٌث١أاخ ٌررثغ 
ؼاٌح. اضافح ٌزٌه   131ا ٚواْ ػذد٘ ATCCاٌؽالاخ اٌرٟ خضؼد ٌرظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح
ؼاٌح لذ خضؼٛا ِٓ لثً ٌرظٛ٠ش اٌششا٠١ٓ اٌراظ١ح  85ؼاٌح خضؼٛا ٌٍمغطشج اٌمٍث١ح تؽ١س شٍّد ػٍٝ  052ذُ دساعح 
ٚرٌه ٌرؽذ٠ذ اٌذلح اٌرشخ١ظ١ح ٌرظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح  ATCCتٛاعطح الأشؼح اٌّمطؼ١ح
والذين  الأخصائيينشخصية مع مختلف  تمقابلا 7ية تم جمعها من خلال بالنسبة للمعلومات النوع .ATCCاٌّمطؼ١ح
القلب والأشعة المقطعية والتصوير  أخصائي تشخيص مرض الشريان التاجي وهم تصوير و يشاركون في عملية
 الطبي.
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 تحليل البياناث
اٚي ذٛضػ اٌرؽٍ١ً اٌٛطفٟ ٚلذ ذُ ػًّ ظذ )SSPS(ذُ ذؽٍ١ً ت١أاخ اٌذساعح تاعرخذاَ تشٔاِط اٌرؽٍ١ً الإؼظائٟ 
 ٌث١أاخ اٌؼ١ٕح ٚأ٠ضا ًذُ ػًّ اٌفؽٛطاخ الإؼظائ١ح اٌّخرٍفح لإ٠عاد ػلالاخ ت١ٓ اٌّرغ١شاخ.
، ٚرٌه ٌرم١ّ١ُ فؼاٌ١ح ذىٍفح الاعرشاذ١ع١اخ فٟ اٌرشخ١ض  meroeht 'seyaBذُ اعرخذاَ ّٔٛرض س٠اضٟ ٠ؼرّذ ػٍٝ 
 ٌّعّٛػاخ اٌّشضٝ اػرّادا ػٍٝ ِذٜ أرشاس اٌّشع.
ذُ ذؼش٠ف فؼاٌ١ح الاخرثاساخ اٌرشخ١ظ١ح تطش٠مر١ٓ ، الأٌٚٝ ِؼ١اس اٌفؼاٌ١ح ٘ٛ لذسج اخرثاس ذشخ١ظٟ ٌرؽذ٠ذ ِشع 
اٌشش٠اْ اٌراظٟ تذلح ٚ٠ّصً ٘زا اٌرؼش٠ف ٔٙعا ِثاششا تافرشاع أْ اٌٙذف اٌٛؼ١ذ ٌلاخرثاس ٘ٛ إظشاء ذشخ١ض طؽ١ػ. 
ؼ١س ِٓ اٌّفرشع  اٌّغرمثٍ١ح ٌٍّشضٝ اٌز٠ٓ ٠خضؼْٛ ٌلاخرثاساخ ٚاٌرؼش٠ف اٌصأٟ ٌٍفؼاٌ١ح ٘ٛ ذفغ١ش إٌرائط اٌظؽ١ح
ِٓ شأٔٗ ذّى١ٓ اٌّشضٝ ِٓ ذٍمٟ اٌؼلاض الأِصً ِّا ٠ؤدٞ إٌٝ ذؽغ١ٓ  أْ اٌرشخ١ض اٌظؽ١ػ ٌّشع اٌشش٠اْ اٌراظٟ
 اٌثماء ػٍٝ ل١ذ اٌؽ١اج تذْٚ ِؼأاج خلاي فرشج اٌّراتؼح.
ٌشعُ الأشىاي   0.7 orp nigirOٌرىٍفح ِٚٓ شُ ذُ اعرخذاَ تشٔاِطاٌؽغاب ٚذؽٍ١ً  )lecxE(ذُ اعرخذاَ تشٔاِط اوغً 
 اٌث١أ١ح اٌرٟ ذٛضػ اٌؼلالح ت١ٓ اٌرىٍفح ٚ اٌفؼاٌ١ح ٚرٌه تٙذف ذؽم١ك أ٘ذاف اٌذساعح.
 نتائج الذراست
٪ ٚ 3.79وأد  ATCC أظٙشخ اٌذساعح أْ ؼغاع١ح ٚخظٛط١ح ذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح
 .٪ 59٪ ٚوأد اٌم١ّح اٌرٕثؤ٠ح اٌغٍث١ح  47.79تالإضافح أْ اٌم١ّح اٌرٕثؤ٠ح الإ٠عات١ح وأد  .٪ ػٍٝ اٌرٛاٌٟ84.09
  ACIتإٌغثح ٌرؽٍ١ً اٌرىٍفح أظٙشخ اٌذساعح أْ اٌرىاٌ١ف اٌّثاششج الإظّاٌ١ح لإظشاء اٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح 
 ذىٍفح إظشاء ذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١حِشج أوصش ِٓ  6.4دٚلاس) ٟٚ٘ ذّصً ؼٛاٌٟ   )32.432
ظٙشخ تشىً ٍِّٛط فٟ ٘زٖ   ACIدٚلاس). اٌرىٍفح اٌغ١ش اٌضشٚس٠ح ٌٍمغطشج اٌمٍث١ح اٌرشخ١ظ١ح )8.05 ATCC
 تغثة ػذَ ٚظٛد   ACI٪ ِٓ اٌّشضٝ ٌُ ٠غرف١ذٚا ِٓ إظشاء اٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح6.34اٌذساعح، ؼ١س أْ 
دٚلاس ٌٍّشضٝ اٌز٠ٓ خضؼٛا ٌٙزا  12662ٌّشع اٌشش٠اْ اٌراظٟ تشىً رٚ أّ٘١ح ٚ ترىٍفح غ١ش ِثشسج لذس٘ا  
 اٌفؽض فٟ ٘زٖ اٌذساعح. 
ٌّشع اٌشش٠اْ اٌراظٟ .  وذاٌح خط١ح لأرشاس  صادخ  ATCCذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح  ذىٍفح
 ٌُ ذض٠ذ تشىً وث١ش. ػٍٝ ٚظٗ اٌرؽذ٠ذ، أظٙشخ اٌذساعح أْ    ACIاٌمٍث١ح اٌرشخ١ظ١حاٌمغطشج  فٟ اٌّماتً ، فئْ  ذىٍفح
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   ACIاٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح ذىٍفح ذىٍفح ألً ِٓ  ATCCذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح ذىٍفح
 ٪.75  أرشاس اوصش ٌِٓٚىٓ اسذفاع اٌرىاٌ١ف ِغ   75٪ ٌّشع اٌشش٠اْ اٌراظٟ تٕغثح الً ِٓ ِغ أرشاس
 ِْي کأْ ٌی سج إلإشادس ا٠ظٌّشع اٌشش٠اْ اٌراظٟ ، ٌطؼ٠ػ ص اٌذکٌفح تأٌعتح ٌٌذشخ٠ز اؼ٠ْ تاٌفؼاٌ٠ح ِق ف٠ِا ٠ذؼٌٚ
فؼاٌح خ کأ   ACIاٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح ٚ ذىٍفح  ATCCذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح
 رشاس ٌّشع اٌشش٠اْ اٌراظٟ.٪ أ 55د ػٔدٚلاس  844تٔعتح 
٪  45أوصش فؼاٌ١ح ِٓ ؼ١س اٌرىٍفح فٟ اٌّشضٝ اٌز٠ٓ ٠ؼأْٛ ِٓ أرشاس ٠ظً إٌٝ  ATCC ٌٚىٓ أظٙشخ اٌث١أاخ أْ 
٪ أرشاس ٌّشع اٌشش٠اْ اٌراظٟ) إٌٝ  01دٚلاس (1.9311 ذرشاٚغ ت١ٓ  DAC ِغ ذىٍفح اٌرشخ١ض اٌظؽ١ػ ِٓ
فؼاٌ١ح   ACI اٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح فٟ اٌّماتً ، أظٙشخ .اْ اٌراظٟ)٪ أرشاس ٌّشع اٌشش٠ 45دٚلاس ( 7.944
٪  65دٚلاس ( 31.634 ٪ ِغ ذىٍفح اٌرشخ١ض اٌظؽ١ػ ت١ٓ   55ٌرىٍفح ِغ ٔغثح الأرشاس اوصش ِٓأفضً ِٓ ؼ١س ا
 ٪ أرشاس ٌّشع اٌشش٠اْ اٌراظٟ). 001دٚلاس (  32.442أرشاس ٌّشع اٌشش٠اْ اٌراظٟ) ٚ 
ِغ فؼاٌ١ح اٌرىٍفح ، واْ ٘زا الاذعاٖ ِّاشلا فؼٕذِا  )YLAQΔ( ك ترؽغٓ ػذد اٌغٕٛاخ اٌّظؽؽح تعٛدج اٌؽ١اجف١ّا ٠رؼٍ
ذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح  ِْي ک٪ واْ  55تٕغثح واْ ِؼذي أرشاس ِشع اٌشش٠اْ اٌراظٟ
 دٚلاس) 051س (تٕفظ اٌمذفؼاٌح خ کأ   ACIاٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح  ATCCاٌّمطؼ١ح
أوصش فؼاٌ١ح ِٓ ؼ١س اٌرىٍفح تإٌغثح ٌرؽغٓ ػذد اٌغٕٛاخ  ATCC ذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح اٌّمطؼ١ح
٪ أرشاس ٌّشع اٌشش٠اْ اٌراظٟ)  إٌٝ  01دٚلاس ( 12.993٠رشاٚغ ِٓ   YLAQΔ اٌّظؽؽح تعٛدج اٌؽ١اج 
 ACI اٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح تأْ فٟ اٌّماتً ، ٠ظٙش ٪ أرشاس ٌّشع اٌشش٠اْ اٌراظٟ). 45دٚلاس ( 60.821
 55.641٪ ، ِغ ٚظٛد ذىٍفح ذرشاٚغ ت١ٓ 001إٌٝ  ٪65 فؼاٌ١ح أفضً ِٓ ؼ١س اٌرىٍفح ِٓ ؼ١س ٔغثح الأرشاس ِٓ 
 ٪ أرشاس ٌّشع اٌشش٠اْ اٌراظٟ). 001دٚلاس ( 97.18 ٪ أرشاس ٌّشع اٌشش٠اْ اٌراظٟ) ٚ  65دٚلاس (
 التوصياث
ِشع  ٠عة أْ ٠ُٕظش ف١ٗ ٌٍّشضٝ اٌز٠ٓ ٠ؼأْٛ ِٓ ACI اٌمغطشج اٌمٍث١ح اٌرشخ١ظ١ح اٌذساعح تشذج تأْ ذٛطٟ
ٚاٌز٠ٓ ذش١ش خظائظُٙ اٌغش٠ش٠ح إٌٝ اؼرّاٌ١ح ػاٌ١ح ٌٛظٛد ذض١ك وث١ش ٚػٕذِا ذؼرثش إٌّافغ أوصش ِٓ  اٌشش٠اْ اٌراظٟ
 ذاس٠ًخا ِشض١ا شاِلاً ٌرم١١ُ اؼرّاي ْ اٌراظٟ٠عة أْ ٠رٍمٝ اٌّشضٝ اٌّشرثٗ فٟ ذؼشضُٙ ٌّشع اٌشش٠ا .اٌخطش
اضافح ٌزٌه ذظٛ٠ش اٌششا٠١ٓ اٌراظ١ح تٛاعطح الأشؼح  .لثً إظشاء اخرثاساخ ذشخ١ظ١ح إضاف١ح ٌّشع اٌشش٠اْ اٌراظٟ
٠ّىٓ أْ ٠ىْٛ ِف١ذا واخرثاس تذسظح أٌٚٝ ٌرم١١ُ اٌّخاطش فٟ اٌّشضٝ اٌّشرثٗ فٟ ذؼشضُٙ ٌّشع  ATCC اٌّمطؼ١ح
 .تذسظاخ ِؼرذٌح إٌٝ ِرٛعطح ٌراظٟاٌشش٠اْ ا
